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Abstract 
Since the early 90’s a new class of inherited neurodegenerative diseases has been 
characterized, the polyglutamine (polyQ) expansion diseases. This group is composed by 
nine progressive and finally fatal disorders. The mutation underlying each one of these 
disorders is an expansion of a CAG trinucleotide repeat that encodes a polyQ tract in the 
respective disease proteins. This polyQ expansion causes the appearance of misfolded 
protein species, which ultimately lead to the formation of aggregates and neuronal loss. 
Although polyQ diseases present different clinical features and neuronal degeneration 
pattern, all these diseases have in common the fact that the associated gene products are 
widely expressed but affect only specific subsets of neurons. This specificity suggests that 
protein misfolding and its toxic outcomes may be determined by the polyQ-flanking 
sequences of the specific disease-associated proteins. Machado-Joseph disease (MJD) or 
spinocerebellar ataxia type 3 (SCA3) is the most frequent autosomal dominant ataxia 
worldwide. Ataxin-3 (ATXN3) is a polyQ protein and expansion of its repetitive glutamine 
tract causes MJD. The economic and social impact of these neurodegenerative diseases has 
led several researchers worldwide to investigate the pathogenesis mechanism and 
therapeutic strategies for polyQ diseases. Animal models, like Caenorhabditis elegans (C. 
elegans), have proved to be an essential tool in this field due to their importance in the 
development of therapeutic trials.  
C. elegans offers unique advantages for examining the aggregation dynamics of 
aggregation-prone proteins and its toxic effects on individual neurons, since the 
transparency of all 959 cells allows easy detection of fluorescent proteins in live animals. 
Despite having relatively few neurons, C. elegans display a wide array of complex 
behaviors and a clear link exists between the behavior and the function of neuronal subsets.  
In this work, we used a C. elegans model of MJD for a screening of therapeutic 
compounds. First, we have tested the effect of a candidate compound targeting 
mitochondrial toxicity: creatine (Cr). We showed that, in our C. elegans model of MJD 
pathogenesis, Cr food supplementation had limited effect in mutant ATXN3-mediated 
neuronal dysfunction and aggregation. Further experiments will be required to determine 
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the treatment effectiveness. Next, in a hypothesis-free approach, we have tested 20 
compounds from an FDA-approved out-of-patent library, and the small molecules Prestw-
38 and Prestw-227 significantly reduced mutant ATXN3-mediated motor impairment.  
In summary, with this work we have identified two compounds that reduced the 
percentage of mutant ATXN3 animals that present locomotion defects, and one of which 
showed a significant reduction in the number of aggregates per area and in the area of 
aggregates per area. It also made available a valuable C. elegans model/tool for drug 
discovery and target identification that can be very useful in future therapy development in 
MJD.  
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Resumo 
Desde o início dos anos noventa, foi caracterizada uma nova classe de doenças 
neurodegenerativas hereditárias, as doenças de expansão de poliglutaminas (poliQ). Este 
grupo é constituído por nove doenças progressivas e fatais. A mutação causadora de cada 
doença é a expansão de uma repetição de um trinucleótido de CAG que codifica um 
segmento de poliQ na proteína causadora da doença. Esta expansão de poliQ está associada 
a uma alteração de conformação das proteínas, com consequente formação de agregados e 
perda de células neuronais. Embora as doenças de poliQ apresentem diferenças clínicas e 
no padrão de neurodegenerescência, todas estas doenças têm em comum o facto de as suas 
proteínas causadoras terem uma expressão ubíqua, mas somente afectarem populações 
específicas de neurónios características de cada uma das doenças. Esta especificidade 
sugere que a agregação proteica e os seus efeitos tóxicos podem ser determinados pela 
sequência aminoacídica de cada proteína. A doença de Machado-Joseph (DMJ) ou ataxia 
espinocerebelosa do tipo 3 (SCA3) é a ataxia autossómica dominante mais frequente em 
todo o mundo. A ataxina-3 (ATXN3) contém um segmento de poliQ cuja expansão está na 
origem da DMJ. O impacto sócio-económico destas doenças neurodegenerativas tem 
levado vários grupos de investigação pelo mundo inteiro a investigar o mecanismo 
patogénico assim como estratégias terapêuticas para as doenças de poliQ. Os modelos 
animais para as doenças de poliQ, por exemplo os Caenorhabditis elegans (C. elegans), 
são uma ferramenta essencial no estudo destas doenças devido à sua enorme importância 
para o desenvolvimento de ensaios terapêuticos.  
O nemátode C. elegans proporciona grandes vantagens no estudo dos efeitos 
tóxicos de proteínas poliQ em neurónios, uma vez que a transparência das suas 959 células 
facilita a detecção de proteínas fluorescentes in vivo. Apesar de apresentarem um número 
reduzido de neurónios, os C. elegans apresentam inúmeros comportamentos complexos, 
existindo uma relação clara entre a função de determinados subtipos neuronais e os 
comportamentos regulados por esses grupos de neurónios.  
Neste trabalho, usamos um modelo transgénico da DMJ em C. elegans para um 
rastreio de compostos terapêuticos. Em primeiro lugar, testamos o efeito da creatina (Cr), 
um composto-candidato que tem como alvo a toxicidade mitocondrial. Demonstramos que, 
no modelo da patogénese da DMJ em C. elegans, o tratamento com Cr teve um efeito 
reduzido na disfunção neuronal e agregação mediados pela ATXN3-mutante. Serão 
necessários novos ensaios para determinar a eficácia deste tratamento. Por fim, testámos 20 
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compostos de uma biblioteca comercial de compostos terapêuticos. Os compostos Prestw-
38 e Prestw-227 demonstraram reduzir significativamente o fenótipo motor do modelo da 
patogénese da DMJ em C. elegans.  
Em resumo, este trabalho permitiu identificar dois compostos que reduziram o 
defeito de locomoção presente no modelo da patogénese da DMJ em C. elegans, um dos 
quais demonstrou também uma redução significativa no número de agregados por área do 
animal e na área de agregados por área do animal. Estes resultados permitiram validar este 
novo modelo animal da DMJ para o rastreio de compostos terapêuticos e identificação de 
alvos que poderão ser úteis para o desenvolvimento de terapias para a DMJ.  
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1.1. Neurodegenerative diseases 
 
Neurodegenerative diseases are devastating disorders, affecting thinking, skilled 
movements, feelings, moods, cognition and memory. This group of diseases includes 
common disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and rarer 
diseases such as Huntington’s disease (HD), spinocerebellar ataxias (SCAs), transmissible 
spongiform encephalopathies (TSEs) and amyotrophic lateral sclerosis (ALS) (Soto, 2003). 
Selective neuronal loss, synaptic abnormalities, neuronal inflammation and the presence of 
cerebral deposits of misfolded protein aggregates are some common characteristics of 
these diseases (Martin, 1999; Soto, 2003). These aggregates are a typical disease mark and 
although the main protein component is different in each disease, they have some similar 
morphological, structural and staining features (Soto, 2003). In addition, the area of the 
brain that is most affected differs among diseases and determines the distinct clinical 
symptoms of each. Though it was initially thought to be the most important problem in 
neurodegeneration, different diseases suggest that extensive neuronal death may not be the 
initial cause of the diseases (Haass, 2007). Certainly, clinical symptoms have been 
described before significant neuronal loss and a better temporal and topographic 
correlation is found with synaptic dysfunction (Haass, 2007).  
 
 
1.2. Protein folding and misfolding 
 
The presence of misfolded proteins within the cellular environment may presents 
two types of critical obstacles to cellular function. Firstly, the function of the misfolded 
proteins is practically always inevitably lost and in the second place, misfolded proteins 
often have a tendency to self-associate and form aggregates. To assist the folding and to 
supervise the maintenance of the folded structure, cells have evolved a highly efficient 
protein folding quality control system, which regulates protein homeostasis and prevents 
accumulation of misfolded protein in the cell (Horwich & Weissman, 1997; Morimoto, 
2002; Nollen & Morimoto, 2002). Some of the foremost identified quality control system 
include: the Heat Shock Protein (HSP) expression, the Unfolded Protein Response (UPR), 
the Ubiquitin-Proteosome System (UPS) and autophagy. The HSPs can assist in the correct 
folding by binding to exposed hydrophobic regions on folding proteins therefore protecting 
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them from aggregation (Hartl, 1996). Within the endoplasmic reticulum, the UPR operates 
as a positive feedback loop increasing the activity of many quality control systems in 
response to an increase in misfolded protein (Kostova & Wolf, 2003). The UPS is a 
surveillance mechanism which primarily functions to target and degrade misfolded or 
aberrant proteins (Ciechanover & Brundin, 2003). Autophagy is a mechanism of 
degradation of intracellular components inside lysosomes (Wang & Klionsky, 2002; 
Cuervo, 2004). Nevertheless, under particular pathological conditions, the ability of this 
machinery is exceeded and aggregation and deposition in tissues are the consequence of 
the failure of the protein folding quality control system (Dobson, 1999; Soto, 2003). This 
failure may result from: mutations affecting the activity of specific chaperones (Evgrafov 
et al., 2004); the damage of the UPS, as occurs in ubiquitin protein catabolic disorders 
(Layfield et al., 2001); the tendency for a specific protein, or a set of proteins, to misfold 
and aggregate, producing disturbances in protein homeostasis, as occurs in a broader class 
of folding disorders called proteinopathies.  
Protein aggregation is the hallmark of an ever-increasing number of diseases. These 
folding diseases, also referred to as protein conformational disorders, include AD, PD, 
HD, SCAs, like spinocerebellar ataxia type 3 (SCA3), type II diabetes, ALS and prion 
diseases such as Creutzfeld-Jakob disease (Dobson, 1999; Soto, 2003).  
 
 
1.3. Polyglutamine (PolyQ) diseases 
 
In the early 1990s, a new mutational mechanism was identified: the expansion of 
unstable trinucleotide repeats (Fu et al., 1991; La Spada et al., 1991; Ross & Poirier, 2004). 
The identification of expanded trinucleotide repeats in various genes has been found to be 
the last cause of a growing number of neurodegenerative diseases. The largest group of 
trinucleotide repeat of neurodegenerative diseases are those due to expansion of a CAG 
repeat located within the coding region of the affected gene. These repeats are translated 
into an extended polyglutamine (PolyQ) tract in the expressed protein, which results in 
protein aggregation within the cell. Of this group, nine diseases associated to expanded 
coding (CAG)n tracts have been described: HD, caused by expansion of (CAG)n tracts in 
the HD gene (Gusella et al., 1983), Kennedy disease or spinobulbar muscular atrophy 
(SBMA), caused by a mutation in the androgen receptor (La Spada et al., 1991), 
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dentatorubral-pallidoluysian atrophy (DRPLA) which is caused by a mutation in atrophin-
1, a transcriptional regulator (Li et al., 1993; Nagafuchi et al., 1994), and several forms of 
SCAs: SCA1, caused by a mutation in ataxin-1 (Orr et al., 1993); SCA2, caused by a 
mutation in ataxin-2 (Pulst et al., 1996); SCA3, also known as Machado-Joseph disease 
(MJD), caused by CAG-repeat expansion in the C-terminal of ataxin-3 (ATXN3) 
(Kawaguchi et al., 1994); SCA6, caused by a mutation in the 1A calcium channel 
(Zhuchenko et al., 1997), SCA7 (David et al., 1997); and SCA17, caused by a CAG 
expansion in TATA-binding transcription factor (Zoghbi & Orr, 2000; Nakamura et al., 
2001). Chromosomal locations of the relevant genes and the names of the translated 
protein products are listed in Table 1.1. 
 Apart from the expanded polyQ tract, that confers toxic properties to the protein, 
these proteins are different from each other. They vary in size and function and enclose the 
glutamine segment at different location within the protein sequence. In spite of generally 
ubiquous patterns of expression, each polyQ containing protein originates a disease-
specific neurodegeneration pattern, suggesting that the protein context plays a role in each 
disease (Burright et al., 1995; Sharp et al., 1995; Trottier et al., 1995; Zoghbi & Orr, 2000).  
 
 
 With the exception of SBMA (which is X-linked), all polyQ diseases are autosomal 
dominant inherited disorders, with a late clinical onset characterized by progressive 
neuronal degeneration with loss of coordination, motor and, in some of these diseases, 
cognitive impairment (reviewed in Zoghbi & Orr, 2000). The transition in polyQ sequence 
Table 1.1- Plolyglutamine Disorders. 
Adapted from Tarlac & Storey, 2003. 
Disorders Locus Protein 
Normal 
(CAG)n 
Expanded 
(CAG)n 
Huntington’s disease 4p16.3 Huntingtin 6-38 36-121 
Spinocerebellar ataxia type 1 6p23 Ataxin-1 6-44 40-81 
Spinocerebellar ataxia type 2 12q24 Ataxin-2 15-29 35-59 
Spinocerebellar ataxia type 3 14q32 Ataxin-3 12-41 55-84 
Spinocerebellar ataxia type 6 19p13 1A Ca+ channel 4-17 20-30 
Spinocerebellar ataxia type 7 3p14 Ataxin-7 4-35 37-220 
Spinocerebellar ataxia type 17 6q27 TATA-binding protein 25-42 45-63 
Dentatorubral-pallidoluysian atrophy 12p13 Atrophin-1 3-35 49-88 
Spinobulbar muscular atrophy 12p13.31 Androgen receptor 11-38 38-62 
Screening of therapeutic compounds in a C. elegans model of Machado-Joseph disease: 
targeting mitochondria. 
6 
 
length from benign to pathological is quite sharp. In general, the pathological threshold 
lengths range from 35 to 50 glutamine residues. The only exception is SCA6, in which the 
threshold ranges from 15 to 20 glutamines (Myers et al., 1998). Within the expanded 
ranges, there is an inverse correlation between the number of CAG repeats and the age of 
disease onset (Gusella & MacDonald, 2000) (see Figure 1.1). The highly expanded CAG 
repeats appeared to be unstably transmitted to succeeding generations with a tendency for 
further elongation, typically in paternal transmission, providing the molecular basis of a 
phenomenon called anticipation (Maciel et al., 1995; Rubinsztein et al., 1996).  
 
 
Figure 1.1- Correlation curves between age-at-onset and number of CAG-repeat length for 
the different polyQ diseases. ‘+’ represent age at onset associated with various CAG repeats 
lengths. The age at onset for homozygotes for the various disorders is also shown (filled circles), 
plotted according to the longer of their two expanded CAG repeats. Adapted from Gusella & 
MacDonald, 2000.  
 
 
1.3.1 PolyQ aggregates 
Nuclear inclusions (NIs) or aggregates have been observed in mice (Ikeda et al., 
1996) and in cell cultures (Chai et al., 1999; Evert et al., 1999) expressing truncated forms 
of MJD proteins. Consistently, Davies and co-workers (1997) reported the presence of an 
age-dependent appearance of NIs in HD exon-1 transgenic mice model and suggested that 
the inclusions were formed through self-aggregation of the polyQ repeat (Davies et al., 
1997). In 1997, DiFiglia and co-workers reported that the polyQ length influenced the 
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extent of huntingtin (Htt) aggregation and accumulation in the HD cortex and striatum 
(DiFiglia et al., 1997). At the same period, Paulson and co-workers (1997) discovered 
ATXN3 aggregates in post-mortem brain tissue of MJD patients (Paulson et al., 1997). 
Moreover, several studies have verified that aggregation occurs in most animal models of 
polyQ diseases, such as Caenorhabditis elegans (C. elegans) (Faber et al., 1999; Satyal et 
al., 2000), flies (Perez et al., 1998; Warrick et al., 1998), mice (Davies et al., 1997; 
Martindale et al., 1998) as well as in cellular models (Scherzinger et al., 1997; Cooper et 
al., 1998). However, the role of NIs of mutant proteins in neurodegeneration remains 
controversial (Ross, 2002) as several other studies suggest that aggregates can function as a 
protective cellular mechanism for stacking the toxic mutant proteins, facilitating their 
degradation (Saudou et al., 1998; Fujigasaki et al., 2001). 
These aggregates are usually detergent-insoluble, and in each disease, are known by 
different names, for example Lewy bodies in PD and plaques or tangles in AD. PolyQ 
aggregates typically have a fribrillar structure under electron microscopy, and aggregates 
are occasionally strained by amyloid binding dyes such as Congo-red or thioflavin-T, 
suggesting that the aggregates take an amyloid-like form (Scherzinger et al., 1997; Huang 
et al., 1998; Chen et al., 2002). And also in each disease aggregates have different aspects 
and locations.  
 
 
1.4. Machado-Joseph disease (MJD) 
 
 MJD is the most common SCA subtype in most populations. The phenotype is one 
of the most variable among SCAs. This disease was first described in North-American 
families of Azorean ancestry, in the 1970s, later in the mainland and then in non-
Portuguese families from all continents (Sequeiros & Coutinho, 1981; Sequeiros & 
Coutinho, 1993).  
Nakano and co-workers reported the first cases, in the Machado family from São 
Miguel in Azores, in 1972; the disease presented as an autosomal dominant ataxia, and was 
named by the authors, “Machado disease” (Nakano et al,. 1972). In the same year, Woods 
and Schaumburg observed the Thomas family, also of Portuguese-Azorean ancestry; 
although resembling that reported by Nakano and co-workers (1972), some clinical 
particularities led the authors to define it as a new clinical entity, and they named “nigro-
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spino-dentatal degeneration” (Wood & Schaumburg, 1972). In 1976, Rosenberg and co-
workers defined a new hereditary ataxia by observation of the Joseph family, originated 
from Flores Island in Azores, which they named as “Joseph disease” (Rosonberg et al., 
1976). A fourth Azorean family was reported to have an “Azorean disease of the nervous 
system” in 1977 (Romanul et al., 1977). Finally, Coutinho and Andrade (1978) studied the 
first 15 families from Azores and proposed that the above mentioned diseases were indeed 
variations of the same clinical disease (Coutinho & Andrade, 1978). Two years later, Lima 
and Coutinho (1980) proposed the name “Machado-Joseph disease” for this clinical entity 
(Lima & Coutinho, 1980). In our days, with families described all over the world, MJD is 
known to be the most common form of dominantly inherited ataxia (15- 45% of all forms 
in different countries and ethnic populations) (Margolis, 2002; Schols et al., 2004; 
Sequeiros et al., 2007).  
 
1.4.1 Clinical features of MJD 
MJD is a progressive neurodegenerative disease, affecting mainly the motor 
function. Patients usually present with ataxia, pyramidal and extrapyramidal signs, 
peripheral amyotrophies, progressive external ophthalmoplegia, intention fasciculation-like 
movements of facial and lingual muscles, rigidy, and bulging eyes (Coutinho & Andrade, 
1978; Lima & Coutinho, 1980; Barbeau et al., 1984; Coutinho, 1992). Importantly, no 
cognitive impairment is observed in MJD patients; this may be a main criterion in the 
differential diagnosis with other SCAs including alterations of the intellect (Coutinho, 
1992). Usually, patients will become confined to a wheelchair and will later be bedridden. 
The median survival time after onset is 20 years. Diseases manifestations typically start 
during adulthood, but the distribution of age at onset is very wide, ranging from 5 to 73 
years (Sequeiros & Coutinho, 1993). 
The high phenotypic variability associated with MJD, led to the organization of the 
disease into four sub-types, occasionally present in the same family, sorted by the age of 
clinical onset and major symptoms of the disorder (Lima & Coutinho, 1980). Sub-type 1 
includes the MJD forms with early age of onset (10-30 years of age), a faster progression, 
and more intense pyramidal and extrapyramidal signs. Sub-type 2 is the most frequent, and 
is characterized by intermediate age-of-onset (20-50 years of age) and progression, with 
patients exhibiting the usual ataxia and ophthalmoplegia and the possible evolution to 
either sub-type. In sub-type 3, patients show the latest age at onset (40-70 years of age), 
slower disease progression and more peripheral signs. A fourth sub-type was added by 
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Rosenberg in 1983; it is the rarest and comprehends MJD patients exhibiting Parkinsonic 
symptoms associated with the more typical MJD symptoms (Rosenberg, 1983; Margolis, 
2002).  
 
1.4.2 Neuropathological features of MJD 
In the 1980s, Coutinho and co-workers defined the pathological criteria of MJD, 
nevertheless, the mechanism of neurodegeneration still remains unknown (Coutinho & 
Sequeiros, 1981). The neuropathological features also show a large variability. 
Pathological examination of post-mortem brains from MJD patients revealed neuronal loss 
and degeneration of specific brain regions, such as cerebellar dentate nucleus, pallidum, 
stratium, substantia nigra (compacta and reticulate), subthalamic, red and pontine nuclei, 
select cranial nerve nuclei and the anterior horn and Clarke’s column of the spinal cord 
(see Figure 1.2) (Robitaille et al., 1997; Schmidt et al., 1998; Iwabuchi et al., 1999; 
Gilman, 2000; Yamada et al., 2004; Koeppen, 2005). Structures such as the cerebral and 
cerebellar cortex and inferior olives are usually spared.  
 
 
Figure 1.2- Brain regions affected in MJD (illustrated in orange). STN: subtalamic nucleus, GP: 
globus pallidus, RN: red nucleus, SN: substantia nigra, PN: pontine nucleus, DN: dentate nucleus, 
LCN: lateral cuneate nucleus, CB: cerebellar cortex. Adapted from Ross, 1995.  
 
Besides neuronal loss, MJD as other polyQ diseases, is characterized by neuronal 
NIs containing expanded polyQ, molecular chaperones, ubiquitin, some components of the 
proteasome and both normal and pathogenic ATXN3 (Paulson et al,. 1997; Perez et al., 
1998; Chai et al., 1999; Nagaoka et al., 2003). In contrast to previous neuropathological 
studies, recent pathoanatomical investigations demonstrated widespread damage to the 
cerebellum, thalamus, midbrain, pons, medulla oblongata and spinal cord in MJD, 
providing suitable explanations for a variety of less understood clinical MJD symptoms 
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(Rub et al., 2003a; Rub et al., 2003b; Rub et al., 2003c Rub et al., 2004; Rub et al., 2005; 
Rub et al., 2006a; Rub et al,. 2006b; Rub et al., 2007).  
 
1.4.3 Genetics features of MJD 
 MJD is transmitted in an autosomal dominant manner, meaning that one copy of the 
defective ATXN3 gene is sufficient for the disease to be transmitted to the offspring 
(Sequeiros & Coutinho, 1981). Intergenerational instability in the transmission of the 
mutated allele is common in MJD. The affected offspring commonly manifest the disease 
earlier in life, with faster progression and aggravated symptomatology. This phenomenon 
of anticipation is common in MJD families (Sequeiros & Coutinho, 1981; Sequeiros & 
Coutinho, 1993). A longer expansion is associated an earlier age of onset and a more 
severe form of the MJD.  
 
1.4.4 The MJD1/ATXN3 gene 
 The mutation associated with MJD is the expansion of a (CAG)n tract in the coding 
region of the MJD1/ATXN3 gene, mapped to the long arm of chromosome 14 (14q24.3-
32.1) in 1993 (Takiyama et al., 1993). The molecular diagnosis of MJD subsequently 
became possible, and the mutation was then confirmed in families of different origins 
(Maciel et al., 1995; Higgins et al., 1996; Lopes-Cendes et al., 1996; Gaspar et al., 2001). 
MJD is caused by the expansion of a CAG repeat in the 3’ coding portion of the gene. The 
repeat is highly polymorphic, ranging from 12-41 repeats units in normal-sized alleles, and 
55-86 in the expanded allele of MJD patients (Maciel et al., 2001). Even though the range 
of repeat lengths with reduced penetrance is not strongly established in MJD as in other 
SCAs, individuals with alleles carrying a CAG repeat between 45-51 have been described 
that may or may not manifest the disorder (Maciel et al., 2001; Gu et al., 2004; Padiath et 
al., 2005). The human MJD1/ATXN3 gene spans 48 Kbp and comprises 11 exons; the CAG 
repeat is located in exon-10 (Ichikawa et al., 2001).  
 
1.4.5 The ATXN3 protein(s) 
The MJD1/ATXN3 gene encodes the protein ATXN3, the smallest of the proteins 
known to be involved in polyQ diseases with a molecular weight around 42kDa in normal 
individuals. The human ATXN3 protein has a conserved N-terminal Josephin domain (JD), 
which is a conserved module named after MJD, containing the putative catalytic triad 
aminoacids cysteine (C14), histidine (H119) and asparagine (N134). Depending on the 
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isoform, ATXN3 is followed by two or three ubiquitin-interacting motifs (UIMs) (Young 
et al. 1998). Bioinformatics analyses showed that ATXN3 also contains a conserved 
nuclear-localization signal (NLS) directly upstream of the polyQ sequence (Tait et al., 
1998). The polyQ stretch of variable in length is in the C-terminus region of ATXN3 
(Kawaguchi et al., 1994).  
 Northern blot analysis revealed ubiquitous ATXN3 expression and suggested the 
existence of four different transcripts with different sizes (1.4, 1.8, 4.5 and 7.5 Kb), 
thought to result from alternative splicing and polyadenylation events, occurring in exons 
2, 10 or 11 (Ichikawa et al., 2001). Five ATXN3 cDNA variants were described: MJD1a, 
MJD1-1, MJD5-1, MJD2-1 and H2 (Kawaguchi et al., 1994; Goto et al., 1997); the latter 
lacks exon 2, but preserves the open reading frame, identical to variant MJD1-1 (Ichikawa 
et al., 2001). A recent study reported fifty-six novel splicing variants of the ATXN3 gene 
from which nineteen are likely to be translated into at least twenty different protein 
isoforms (Bettencourt et al., 2010). The physiological and clinical relevance of these new 
variants remains to be determined.  
 ATXN3 is expressed throughout the body and in all regions of the brain, including 
areas generally spared by the disease (the cerebral cortex) (Trottier et al., 1995; Paulson et 
al., 1997; Wang et al., 1997). ATXN3 is highly present in the cytoplasm of most cells, but 
can be present also in the nucleus and has been associated with the nuclear matrix, 
endoplasmic reticulum (ER) and mitochondria (Paulson et al., 1997; Schmidt et al., 1998; 
Tait et al., 1998; Trottier et al., 1998; Fujigasaki et al., 2000). As in other polyQ diseases, 
the abnormal and normal allele products were shown to be equally expressed in 
lymphoblastoid cells and in the brain of MJD patients (Paulson et al., 1997; Wang et al., 
1997). Isoform 1 (3 UIMs) is the most abundant ATXN3 isoform in brain of patients and 
transgenic mice (Harris et al., 2010).  
 ATXN3 homologous genes are present in different organisms, including plants, 
nematodes and humans. Several proteins have been identified that display high homology 
to human ATXN3 in other species, namely, Rattus norvegicus 88% (Schmitt et al., 1997), 
Mus musculus 88% (Costa et al., 2004), Gallus gallus 82% (Linhartova et al., 1999), C. 
elegans 38% (Rodrigues et al., 2007), and other organisms. Curiously, the long polyQ tract 
seems to be human-specific because it is absent in other species such as mouse and C. 
elegans, which have only six and one glutamines in their ATXN3 homologues, 
respectively.  
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1.5. Pathogenic mechanisms of polyQ diseases 
 
 PolyQ disorders are characterized clinically by the constant progression of the 
symptoms and by the protein accumulation inside neurons causing their dysfunction and 
ultimately death. Although it has been years since the identification of the genetic basis of 
polyQ diseases, their molecular basis is still controversial. Several cellular and molecular 
mechanisms have been proposed to explain polyQ pathogenesis (see Figure 1.3).  
 
 
Figure 1.3- Molecular mechanisms underlying pathogenesis of polyQ diseases. Hypothetical 
pathway of conformational change, oligomerization and formation of inclusion bodies. The native 
expanded polyQ monomer undergoes conversion to a misfolded β-sheet conformation, resulting in 
formation of NIs through assembly of oligomeric intermediates. Expanded polyQ proteins may 
exert toxicity as a misfolded monomer or toxic oligomers. The major toxic effects of these 
structures may involve alterations in transcription, impairment of the UPS, mitochondrial 
dysfunction, dysregulation of intracellular Ca2+ homeostasis, impairment of axonal transport and 
genotoxic stress in polyQ diseases. Adapted from Takahashi et al., 2010.  
 
1.5.1 Mitochondrial dysfunction in polyQ diseases  
Considering that mitochondrial dysfunction may originate from mutations in more 
than 1000 genes (Larsson & Clayton, 1995), from the deleterious effects of many toxic 
compounds (Kovacic et al., 2005), and even occur spontaneously during ageing (Reeve et 
al., 2008), it is almost not surprising that mitochondrial disorders are much more frequent 
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than previously thought (Elliott et al., 2008). The mitochondrial theory of 
neurodegeneration and aging implies that reactive oxygen species (ROS), mitochondrial 
DNA (mtDNA) damage, and progressive respiratory chain defect are mutually interacting 
in a vicious circle (Harman, 1972; Bender et al., 2006).  
Protein aggregates might induce oxidative stress by producing free radical species, 
resulting in protein and lipid oxidation, elevation of intracellular calcium levels and 
mitochondrial dysfunction (Behl et al., 1994; Hsu et al., 2000). Oxidative stress has been 
shown to contribute to the pathogenesis of many polyQ diseases (Bence et al., 2001; 
Butterfield & Kanski, 2001; Imaizumi et al., 2001; Martindale & Holbrook, 2002). A 
cellular condition of oxidative stress develops when the mitochondrial oxidative 
phosphorylation and the cell’s antioxidative capacity become overloaded. In these 
conditions, ROS are generated in excess and damage to the cell and its DNA, RNA, lipid 
and protein constituents may possibly occur. In this context, misfolded protein structures 
may be particularly susceptible to oxidative modifications, which may promote unfolding 
and thus increase the susceptibility to further modifications that exaggerate the stress 
responses (Dukan et al., 2000). Although the exact mechanisms and order of events may be 
quite different in the various polyQ diseases, the result seems similar: chronic stress and 
ultimately death of the cell.  
Oxidative stress related with deficiency of the oxidative phosphorylation and the 
induction of stress responses are well established as part of the gain-of-function occurring 
in neurodegenerative diseases. Deficient activity of components of the mitochondrial 
respiratory chain (MRC) has been found in brain cells of patients with AD, PD and HD 
(Butterfield & Kanski, 2001; Mattson et al., 2002). Biochemical analyses of the brain of a 
HD patient showed abnormal aspects of energy metabolism, including reduced glucose 
metabolism, decreased mitochondrial complex activity and increased lactate concentration 
(Browne et al., 1997). Reduced concentrations of creatine (Cr) and phosphocreatine (PCr) 
have been observed in the basal ganglia of HD patients (Sanchez-Pernaute et al., 1999). In 
addition, mitochondria from HD patients and HD transgenic mice exhibited lower 
membrane potentials and required lower calcium loads for depolarization than 
mitochondria from controls (Sawa et al., 1999; Panov et al., 2002). These findings 
reinforcing the idea that oxidative stress and mitochondrial dysfunction play an important 
role in polyQ diseases pathogenesis.  
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Yu and co-workers (2009) demonstrated that mtDNA copy numbers are decreased in 
mutant cells and MJD patient’s leukocytes samples compared with the normal controls. 
Furthermore, the amount of the common mtDNA 4,977-bp deletion is higher in MJD 
patients compared with that in normal individuals. These results suggest that the cell 
damage caused by greater oxidative stress in MJD mutant cells plays an important role, at 
least in part, in the disease progression. (Yu et al., 2009).  
 
 
1.6  Therapeutic approaches for polyQ diseases 
 
There is no effective cure for MJD and all other polyQ diseases. The lack of 
therapeutic approaches that effectively prevent neurodegeneration in MJD patients 
prompted us to search for compounds that modulate mutant ATXN3 aggregation and the 
associated neurological dysfunction. 
Potential therapeutic approaches for polyQ diseases could be divided into two 
classes: those targeting directly the mutant proteins and those targeting the toxic effects of 
the mutant proteins such as mitochondrial dysfunction and oxidative stress, transcriptional 
abnormalities, autophagy, UPS impairment, excitotoxicity, or apoptotic pathways such as 
preventing the cellular damage (Bauer & Nukina, 2009) (see Figure 1.4).  
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Figure 1.4- Summary of therapeutic approaches for polyQ diseases. Blue background 
highlights the hypothetic processing of the mutant polyQ protein. Molecules targeting different 
events in polyQ disease pathogenesis (black boxes) are displayed in red boxes. Written in red are 
molecules targeting mitochondrial dysfunction. Adapted from Bauer & Nukina, 2009.  
 
 
Few research papers focused on developing therapies for MJD have been published 
to date. Chen and co-workers (2008) found that administration of dantrolene (a clinically 
relevant stabilizer of intracellular Ca2+ signaling) improved motor performance and 
prevented neuronal cell loss in the pontine nuclei and substantia nigra of the transgenic 
mouse model SCA3-YAC-84Q (Chen et al., 2008). Their results indicate that deranged 
Ca2+ signaling may play an important role in MJD pathology and that Ca2+ signaling 
stabilizers such as dantrolene may be considered as potential therapeutic drugs for 
treatment of MJD patients.  
Menzies and co-workers (2010) showed that cell cycle inhibitor-779 (CCI-779) 
treatment (a water soluble rapamycin ester which demonstrates the same activity as 
rapamycin) significantly improved motor performance in a transgenic mouse model of 
MJD (a transgenic mice expressing mutant full-length ATXN3 with an expanded polyQ 
repeat region of 70 residues), decreased the number of ATXN3-positive aggregates seen in 
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the brains of transgenic mice and also decreased soluble mutant ATXN3 levels (Menzies et 
al., 2010). CCI-779 is designed for long-term use in patients and therefore represents a 
possible therapeutic strategy for the treatment of MJD.  
Chou and co-workers (2011) tested the hypothesis that HDAC inhibitor sodium 
butyrate (SB) alleviates ataxic symptoms of MJD transgenic mice by reversing ataxin-3-
Q79-induced histone hypoacetylation and transcriptional repression. SB treatment 
significantly reversed ATXN3-Q79-induced histone hypoacetylation and transcriptional 
downregulation in the cerebellum of ATXN3-Q79 transgenic mice and also delayed the 
onset of ataxic symptoms, improved neurological phenotypes and improved the survival 
rate of ATXN3-Q79 transgenic mice (Chou et al., 2011). Their results suggest that SB 
might be a promising therapeutic agent for MJD.  
 
1.6.1 Therapeutic approaches to polyQ diseases: targeting mitochondria 
As mentioned before, damage of mitochondrial functions is one of the key events in 
polyQ diseases leading to cell death by activation of apoptotic cascades. The process of 
mitochondrial dysfunction is accompanied by impaired respiration; stress-induced 
mitochondrial depolarization; increased free radical production, with oxidative damage; 
and globally abnormal energy metabolism in polyQ diseases (Grunewald & Beal, 1999; 
Panov et al., 2002; Browne & Beal, 2006).  
 
Different compounds improving energy metabolism defects or reducing oxidative 
stress in polyQ diseases have been successfully tested in mouse models. Antioxidants such 
as α-lipoic acid, coenzyme Q10 (CoQ10) clioquinol, tauroursodeoxycholic acid (also with 
antiapoptic affects), and BN82451 have been proven effective in the R6/2 mouse lines of 
HD (Giampa et al., 2009). As mentioned before, reduced concentrations of Cr and PCr 
were observed in basal ganglia of HD patients (Sanchez-Pernaute et al., 1999); 
accordingly, in two mouse models of HD, Cr administration stabilized the mitochondrial 
permeability transition (MPT), prevented ATP depletion, increased the protein synthesis 
(Ferrante et al., 2000; Andreassen et al., 2001) and also ameliorated motor symptoms and 
the brain pathology.  
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1.6.2 Creatine (Cr), Phosphocreatine (PCr) and Creatine Kinase (CK) 
Cr [α-methyl-guanidinoacetic acid] is a natural substance in vertebrates and helps to 
supply energy to muscle and nerve cells. In humans, Cr is taken up from the food, 
especially meat and fish, (approximately 1-2 g/day) by intestinal absorption (Khan & 
Cowen, 1977; Dvorak, 1981). Cr is also synthesized endogenously mainly in the kidney, 
pancreas, and liver (approximately 1-5 g/day) by the action of arginine: glycine 
amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT). 
Cr is taken up into the muscle and brain by a sodium-dependent active 
transmembrane creatine transport system (CrT) and becomes physiologically active when 
it is transformed enzymatically into PCr. The Cr/PCr system, regulated by the 
mitochondrial creatine kinase (CKMi), plays an essential role in maintaining the high 
energy levels necessary for brain development and functions, through regeneration and 
buffering of ATP/ADP levels (Wallimann et al., 1992, 2007; Wyss & Kaddurah-Daouk, 
2000; Brosnan & Brosnan, 2007; Andres et al., 2008). Intracellular Cr and PCr are non-
enzymatically converted, at an almost constant rate constant (of 1.5%/day) of body Cr, into 
creatinine (Crn), which passively diffuses out of the cells and is excreted by the kidneys 
into the urine. The daily urinary Crn excretion is directly proportional to the total Cr stores 
in the body (Greenhaff ,1997). Cr loading by adults at a rate of 5 g/day for 5 days increases 
arterial Cr levels (Poortmans et al., 1997). In muscle, PCr levels can rise an average of 
20% accompanied by a 20% mean increase in peak work performance (Greenhaff, 1997) 
and a loss of fat, and increase of lean body mass (Vandenberghe et al., 1997).  
 
As mentioned before, the Cr/PCr system is thought to be physiologically important 
in tissues with high and variable energy requirements, like brain and muscle (Wallimann & 
Hemmer, 1994). In these cells, high-energy PCr serves not only as an immediate temporal 
energy buffer, but also as an energy shuttle from subcellular sites of energy production 
(mitochondria and/or glycolysis) to sites of energy consumption (ion pumps and various 
other ATPases) where creatine kinase (CK) isoenzymes are specifically localized in a 
compartmented fashion (Bessman & Geiger, 1981; Wallimann et al., 1992) (see Figure 
1.5). In the cytoplasm and membrane compartments of neurons, as well as glial cells in 
culture (Manos et al., 1991; Molloy et al., 1992) and in vivo (Hemmer et al, 1994; Kaldis et 
al., 1996), CK isozyme BB catalyzes the reversible conversion of PCr and ADP to ATP 
and Cr to manage different aspects of demands in the brain (Hemmer & Wallimann, 1993; 
Chen et al., 1995). On the other hand, CKMi catalyzes the reversible conversion of Cr and 
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ATP to ADP and PCr to generate energy reserves in the cytoplasm (Wyss et al., 1992). PCr 
reserves are depleted even more rapidly than ATP during ischemia (Passonneau & Lowry, 
1971) owing to their conversion to ATP by CK.  
Although the brain constitutes only 2% of the body mass, it can be responsible for 
up to 20% of total energy consumption under resting conditions. Accordingly, it 
necessitates a significant ATP turnover in order to maintain membrane potentials as well as 
the signaling activities of the central and peripheral nervous system. The presence of CK 
isoforms in the brain and spinal cord underlines the energetic role of Cr/PCr system on 
central nervous system (CNS) (Andres et al., 2008).  
 
Figure 1.5- Relationship of Cr and PCr to ATP in the neuron. Exogenous Cr should be readily 
transported into neurons by a CrT or synthesized if precursors are available (Dringen et al., 1998). 
Under resting levels of ADP, ATP produced in the mitochondria is converted to PCr by CKMi and 
released into the cytoplasm. In the cytoplasm, the equilibrium constants for brain CK and CKBB 
(Quest et al., 1990; Boehm et al., 1996, 1998). Adapted from Brewer & Walliman, 2000; drawn 
from information on rat heart and chick brain.  
 
1.6.3 Cr supplementation on neurodegenerative diseases 
One potential mechanism of neuroprotection of Cr is buffering of intracellular 
energy stores by increasing PCr levels. CK is also coupled directly or indirectly to 
energetic processes required for Ca2+ homeostasis (Wallimann et al., 1992; Steeghs et al., 
1997).  
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The interest in the Cr/PCr system and, consequently, Cr supplementation effects on 
the CNS is relatively recent. The fact that exogenous Cr is able to cross the blood–brain 
barrier (BBB) and increase the cerebral Cr concentration has generated interest in the 
scientific community, since several neurological diseases are associated with reduced 
cerebral Cr content. The promising effects of Cr supplementation on neurodegenerative 
diseases are notable (see Table 1.2).  
 
Table 1.2- 
Clinical trials investigating the effects of Cr supplementation on neurodegenerative diseases. 
Adapted from Andres et al., 2008.  
 
Authors and year Disease (n) Study Design Cr Protocol Effect 
Mazzini et al., 2001 ALS (28) Open trial 
20 g/day for 
7days + 3 
g/day for 
6months 
↑Isometric 
power 
Shefner et al., 2004 ALS (104) 
Randomized, 
double-blind, 
placebo-controlled 
20 g/day for 
5days + 5 
g/day for 
6months 
None 
Tabrizi et al., 2003 HD (13) Open trial 10 g/days for 1year 
Possible 
stabilization 
of signsa 
Bender et al., 2005 HD (20) Open trial 
20 g/days for 
5days + 6 
g/days for 8–
12weeks 
↓[Glutamate] 
Tabrizi et al., 2005 HD (13) Open trial 10 g/days for 2years 
Possible 
stabilization 
in some 
patientsa 
Hersch et al., 2006 HD (64) 
Randomized, 
double-blind, 
placebo-controlled 
8 g/days for 
16weeks 
↓Oxidative 
stress 
Bender et al., 2006 PD (60) 
Randomized, 
double-blind, 
placebo-controlled 
20 g/days for 
6days + 2 
g/days for 
6months + 
4 g/days 
for 18months 
↑Mood 
NINDS NET-PD, 2006 PD (134) 
Randomized, 
double-blind, 
placebo-controlled 
10 g/days for 
1year 
Not 
considered 
futileb 
Hass et al., 2007 PD (20) 
Randomized, 
double-blind, 
placebo-controlled 
20 g/days for 
5days + 5 
g/days for 
12weeks 
↑Muscle 
function 
↑Strength 
↑ = improved or increased, ↓ = decreased 
aAs inferred by the lack of disease deterioration 
bA treatment is considered futile when it does not show good therapeutic value 
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 There is ample evidence showing the presence of CK in pyramidal cells, which are 
involved in memory and learning processes (Kaldis et al., 1996). In light of this, some 
investigations have addressed the effects of Cr supplementation on the cognition process.  
 ALS is a severe neurodegenerative disease that occurs with progressive motor 
neuron loss (Andres et al., 2008). In transgenic rats mimicking this disease, reductions in 
ATP content (Browne et al., 2006) and CK activity were observed (Wendt et al., 2002). 
Moreover, Cr supplementation seems to present neuroprotective properties in the same 
model, likely due to its direct antioxidant capacity or via the energetic role of the Cr/PCr 
system (Dupuis et al., 2004). Oral supplementation with 1 and 2% Cr in the ALS mouse 
model starting at 70 days of age protected against the loss of neurons in both the motor 
cortex and the substantia nigra, reduced the level of oxidative damage, produced a dose-
dependent improvement in motor performance and extended survival (Klivenyi et al., 
1999). In spite of these promising findings in animal models, the first clinical trials did not 
reveal significant benefits in ALS patients (see Table 1.2).  
 AD is a common disease characterized by dementia. Cerebral CK expression seems 
to be reduced in patients with this disease (Aksenov et al., 1997). Appreciably, it has been 
demonstrated that Cr exerts neuroprotective effects on neurons cultivated in neurotoxic 
media, induced by glutamate and β-amyloid protein (Brewer & Wallimann, 2000). 
Nevertheless, clinical trials are needed to assess whether Cr supplementation can be an 
effective approach against AD.  
As revealed before, HD is an autosomal dominantly inherited neurodegenerative 
disease that clinically occurs with progressive movement loss and important cognitive and 
emotional dysfunction (Andres et al., 2008). There is evidence linking the severity of this 
disease to increased lactate concentration, decreased muscle PCr content, and 
mitochondrial dysfunction (Grunewald & Beal, 1999). Accordingly, Cr supplementation 
was proposed to be an appropriate therapeutic approach to prevent the gradual neuronal 
loss. Ferrante and co-workers (2000) placed HD transgenic mice (line 6/2) and wild-type 
(WT) littermates on either unsupplemented diets or diets supplemented with 1, 2 or 3% Cr 
at 21 days of age. Cr supplementation significantly improved body weight and motor 
performance, delayed the onset of diabetes present in this particular model, and reduced 
the development of brain atrophy, loss of striatal neurons and formation of Htt-positive 
aggregates (Ferrante et al., 2000). Cr also exerted similar therapeutic effect in another 
transgenic mouse model of HD (N171-82Q) (Adreassen et al., 2001). Clinical studies in 
patients with HD have demonstrated that Cr supplementation reduces oxidative stress 
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(Hersch et al., 2006) and glutamate concentration (Bender et al., 2005); in addition to 
normalizing cerebral Cr content (Ryu et al., 2005).  
 PD is characterized by a predominant and progressive loss of dopaminergic neurons 
in the substantia nigra, resting tremor, bradykinesia, rigidity, and postural imbalance 
(Andres et al., 2008). Evidence indicates that a defect in electron transport chain might be 
involved in the physiopathology of PD (Schapira et al., 1990; Alam & Schmidt, 2002), 
which suggests that therapeutic strategies focused on improvement in mitochondrial 
function may be promising. In vitro experiments mimicking PD revealed that Cr has 
protective effects against neurotoxic insults. Systemic administration of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces parkinsonism in experimental animals 
by a mechanism involving impaired energy production. MPTP is converted by monoamine 
oxidase B to 1-methyl-4-phenylpyridinium (MPP1), which blocks complex I of the 
electron transport Chain (Matthews et al., 1999). Matthews and co-workers (1999) found 
that oral supplementation with each 1% Cr or 1% cyclocreatine for 2 weeks produced 
significant protection against MPTP-induced dopamine depletion in mice. Using an 
experimental in vitro paradigm of PD, Andres and co-workers (2005) observed 
neuroprotective effects of Cr against toxic insults induced by 6-hydroxydopamine (6-
OHDA) (Andres et al., 2005a) or 1-methyl-4-phenyl pyridinium (MPP+) (Andres et al., 
2005b) exposure in ventral mesencephalic rat cultures. Nevertheless, the results of clinical 
studies in PD patients remain controversial (Bender et al., 2006; Hass et al., 2007).  
 
 
1.7  Animal models for MJD 
 
Appropriate disease model systems are an essential tool in understanding the 
molecular mechanism underlying the pathogenesis and in development in therapeutic 
approaches. Cell culture and mouse models continue to be mainstays to complement study 
of many diseases for their complexity and simplicity, respectively. In recent times, 
invertebrate models (flies and worms) have started been used to great advantage in the 
study of neurodegenerative disease (Link, 2001; Driscoll & Gerstbrein, 2003; Thompson & 
Marsh, 2003; Westlund et al., 2004).  
Since the discovery of the disease-causing gene in MJD (the mutant ATXN3 gene), 
several in vitro (Evert et al,. 1999; Yoshizawa et al., 2000; Yoshizawa et al., 2001) and in 
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vivo (Ikeda et al., 1996; Warrick et al., 1998; Cemal et al., 2002; Goti et al., 2004; 
Bichelmeier et al., 2007; Alves et al., 2008; Chou et al., 2008; Boy et al., 2009; Boy et al., 
2010; Silva-Fernandes et al., 2010; Teixeira-Castro et al., 2011a) models have been 
developed, in order to investigate the underlying pathology, identify factors and pathways 
that modify the disease process, and test potential therapeutic approaches. These MJD 
models have been developed using mouse and rat, the fruitfly Drosophila melanogaster 
and the nematode C. elegans. The following is a succinct description of MJD animal 
models available to data.  
 
1.7.1 Mouse models of MJD 
The first MJD mouse model was generated expressing the complete and truncated 
cDNAs of MJD1/ATXN3 gene specifically in the Purkinje cells of the cerebellum (slightly 
affected in MJD). The transgenic mice expressing the C-terminal ATXN3 with 79Q were 
ataxic, displayed cerebellar atrophy and Purkinje cells loss, four weeks after birth (Ikeda et 
al., 1996). 
Since 1996, seven additional mouse models have been generated (Cemal et al., 
2002; Goti et al., 2004; Bichelmeier et al., 2007; Chou et al., 2008; Boy et al., 2009; Boy et 
al., 2010; Silva-Fernandes et al., 2010). Cemal and co-workers (2002) generated transgenic 
mouse models using a yeast artificial chromosome (YAC) containing MJD1 gene with 64 
and 84 CAG repeats (Cemal et al., 2002). Animals with the expanded alleles developed a 
very mild and slowly progressive cerebellar deficit, manifesting as early as 4 weeks of age. 
NIs and cell loss were observed in the pontine and dentate nuclei, with variable affection of 
the cerebellar cortex and of Purkinje cells. As the disease progressed, pelvic elevation 
became markedly flattened, and this was accompanied by hypotonia, and motor and 
sensory loss. This mouse was the first model described expressing the full length MJD1 
gene under the control of its own regulatory elements. Goti and co-workers (2004) had 
observed a much more severe phenotype in a mouse model expressing human expanded 
ATXN3 (variant MJD1a) with Q71 or normal ATXN3 (Q20) under the control of a mouse 
prion protein promoter (moPrP). Q71 transgenic mice expressing mutant ATXN3 above a 
critical level experienced a phenotype similar to MJD including progressive postural 
instability, gait and limb ataxia, weight loss, premature death, neuronal intranuclear 
inclusions, and decreased tyrosine hidroxylase -positive neurons in the substantia nigra. 
Q20 transgenic mice had normal behavior and pathology. Interestingly, a C-terminal 
cleavage fragment of the transgene product has been revealed in this model, which the 
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researchers also observed in human patients’ post-mortem brains (Goti et al., 2004). The 
group of Olaf Riess (2007) developed another MJD transgenic mouse model expressing the 
full-length ATXN3 with 15, 70 or 148 CAG repeats under the control of the moPrP 
transgenic mice for ATXN3 with 15 CAG repeats were normal with no signs of 
neurodegeneration, while mice expressing mutant ATXN3 with (70 and 148 CAG repeats) 
displayed a neurological phenotype including reduced motor and exploratory activity, 
tremor and premature death by 3 to 6 months. ATXN3 and Ub-positive inclusions were 
observed in almost all brain with the exception of Purkinje cells. Q148 mice displayed a 
more severe neurological phenotype with more inclusions and earlier death when 
compared with mice expressing mutant ATXN3 with 70 CAG repeats. The authors proved 
that the nuclear localization of the mutant protein is crucial for pathogenesis to occur 
(Bichelmeier et al., 2007). In 2008, a new transgenic mouse model was generated 
expressing the human ATXN3 cDNA containing 79 CAG repeats, under the moPrP. These 
transgenic mice displayed motor dysfunction with an onset age of 5–6 months, and 
neurological symptoms deteriorated in the following months. A prominent neuronal loss 
was not found in the cerebellum of 10 to 11-month-old ATXN3-Q79 mice displaying 
pronounced ataxic symptoms, suggesting that instead of neuronal demise, ATXN3-Q79 
causes neuronal dysfunction of the cerebellum and resulting ataxia (Chou et al., 2008). In 
order to analyze whether symptoms caused by ATXN3 with an expanded repeat are 
reversible in vivo, a conditional mouse model of MJD with the full-length human ATXN3 
cDNA with 77 repeats was created using the Tet-Off system (Boy et al., 2009). The 
trangenic mice developed a progressive neurologic phenotype characterized by neuronal 
dysfunction in the cerebellum, reduced anxiety, hyperactivity, impaired rotarod 
performance and decreased gain of body weight. After turning off the expression of the 
expanded ATXN3 at an early symptomatic stage of the disease the observed motor 
symptoms regressed and after five months of treatment, transgenic MJD mice were 
indistinguishable from their controls suggesting that both neurological and physiological 
symptoms of MJD are reversible. The same group published another MJD transgenic 
mouse model expressing ATXN3 with 148 CAG repeats under the control of the Htt 
promoter, resulting in ubiquitous expression throughout the whole brain (Boy et al., 2010). 
The model resembles many features of the disease in humans, including a late onset of 
symptoms and CAG repeat instability in transmission to offspring. They observed a 
biphasic progression of the disease, with hyperactivity during the first months (not seen in 
Screening of therapeutic compounds in a C. elegans model of Machado-Joseph disease: 
targeting mitochondria. 
24 
 
human patients) and a decline of motor coordination after about 1 year of age; however, 
NIs were not visible at this age, but only at the age of 18 months. 
Recently, our lab generated two transgenic mouse lineages expressing the expanded 
human ATXN3 under the control of the cytomegalovirus promoter (pCMV): CMVMJD83 
and CMVMJD94, carrying Q83 and Q94 stretches, respectively. Behavioral analysis 
revealed that the CMVMJD94 transgenic mice developed motor uncoordination, 
intergenerational instability of the CAG repeat and a tissue-specific increase in the somatic 
mosaicism of the repeat with aging. Histopathological analysis of MJD mice at early and 
late stages of the disease revealed neuronal atrophy and astrogliosis in several brain 
regions; however, they found no signs of microglial activation or neuroinflammatory 
response prior to the appearance of an overt phenotype. In this model, the appearance of 
MJD-like symptoms was also not associated with the presence of ATXN3 cleavage 
products or NIs. The transgenic CMVMJD94 mice as a useful model to study the early 
stages in the pathogenesis of MJD and to explore the molecular mechanisms involved in 
CAG repeat instability (Silva-Fernandes et al., 2010).  
All these MJD transgenic mouse models suggest that despite the expression of 
mutant ATXN3 in the whole brain, there are considerable differences in the affected brain 
regions and cell types. However, no model has yet completely reproduced the pathological 
and clinical symptoms observed in MJD patients.  
 
1.7.2 Rat model of MJD 
Overexpression of mutant ATXN3 in the rat brain using lentiviral vectors (LV) led 
to neuropathological abnormalities: formation of ubiquitylated ATXN3 aggregates, alpha-
synuclein immunoreactivity and loss of dopaminergic markers (TH and VMAT2). Alves 
and co-workers (2008) proposed striatal pathology as contributing factors for the dystonia 
and chorea observed in some MJD patients (Alves, et al., 2008).  
 
1.7.3 Drosophila melanogaster models of MJD 
The first transgenic Drosophila melanogaster model of a human neurodegenerative 
disease was obtained for MJD (Warrick et al., 1998) and demonstrated formation of 
neuronal inclusions and late-onset cell degeneration. Interestingly, different sensitivity to 
the expanded protein has been observed among different cell types, the neurons being 
particularly susceptible. More recently, the same group, using the Drosophila 
melanogaster model, has established a direct link between normal protein function and 
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disease pathogenesis, namely in relation to ubiquitin pathways in MJD. Their findings 
underline the importance of the normal function of normal ATXN3 in MJD pathogenesis 
and suggest a potential protective role of ATXN3 activity for polyQ diseases (Warrick et 
al., 2005). Thus, Drosophila melanogaster models have significantly contributed to our 
growing understanding of the molecular bases of MJD.  
 
1.7.4 C. elegans models for MJD 
As described in more detail later, C. elegans systems represent an attractive 
intermediate model system by combining sufficient complexity to allow investigation of 
both cellular and behavioral phenotypes with a simplicity that facilitates rapid, high‐
throughput testing of hypotheses.  
Khan and co-workers (1996) described a study of the pathogenic effects of polyQ 
expanded tracts within the context of ATXN3 (Khan et al., 2006). Full-length ATXN3 
(variant MJD1a) was expressed in C. elegans nervous system under the regulation of the 
unc-119 promoter, which is first active at the pre-comma embryonic stage (Altun-Gultekin 
et al., 2001). Animals expressing full-length ATXN3 with 130 glutamines showed age-
dependent aggregation and toxicity (only in animals 7 days-old or more). In contrast, 
expression of a truncated form of ATXN3 (containing only the polyQ domain and C-
terminal region) caused polyQ length-dependent aggregation and toxicity. Additionally, 
expanded polyQ proteins caused interruption of the synaptic transmission and induced 
swelling and abnormal branching of neuronal processes (Khan et al., 2006). All neurons 
showed equal susceptibility to the expression of expanded polyQ proteins.  
 Teixeira-Castro and co-workers (2011) have established a new C. elegans model of 
MJD in which ATXN3 was expressed throughout the nervous system. In this model, 
expression of both full-length and truncated forms of ATXN3, with different Q-lengths, 
results in a consistent pattern of neuronal cell-type specific aggregation, with the ventral 
and dorsal nerve-cord neurons being highly affected, while some lateral interneuron cell 
bodies are resistant. Certain sensory processes in the head contain aggregated foci, but only 
when the polyQ stretch is within the ATXN3 protein flanking sequences and not when 
expressed alone. They have also studied the impact of aging and of reprogramming 
animals’ survival in their model, and found that reducing 1-like signaling (IIS) and 
activating heat-shock factor 1 (HSF-1) pathways (genetically or pharmacologically) 
reduced pathogenesis, supporting the mechanistic links between the aging process and 
neuronal toxic-protein aggregation, which are common hallmarks of neurodegenerative 
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disorders (Teixeira-Casto et al, 2011). They found that full-length ATXN3 aggregates only 
at high Q-length (AT3q130), and not with a WT Q-length (AT3q14).The presence of 
aggregated protein was confirmed by biophysical approaches (FRAP). Interestingly, 
AT3q130 proteins did not form aggregates in all C. elegans neuronal cells. This data 
suggested that this C. elegans model recapitulates an important aspect of polyQ diseases - 
the neuronal subtype-specific inclusion body formation. Therefore, this AT3q130 C. 
elegans model mimics MJD in many aspects, namely by showing a polyQ-length 
dependent aggregation that directly correlates with a progressive neurological dysfunction 
(Teixeira-Casto et al., 2011a).  
 
 
1.8. C. elegans as a model system 
 
 Due to the complexity of the vertebrate brain and the fact that mammalian model 
organisms have their own limitations (e.g. cost, laborious transgenesis, long life spans), 
invertebrate models including C. elegans have been used in the past decade to delineate the 
molecular mechanisms underlying neurodegeneration.  
 C. elegans is a small, bacteriovorous nematode (or roundworm) found commonly in 
many parts of the world, first described by Emile Maupas in 1900 (Maupas, 1900). In 
1960s Sydney Brenner selected C. elegans as a simple model for his intensive studies of 
the genetics and development of the nervous system, due to its characteristics as a model 
organism (Brenner, 1974). 
 
Caenorhabditis elegans (Caeno: recent; rhabditis: rod; elegans: nice) is a free-
living, non-parasitic soil nematode that can be safely used in the laboratory. C. elegans is 
transparent, small (two sexes, hermaphrodites and males, are each about 1mm in length as 
an adult) but easy to visualize under the microscope. It thrives in simple Petri-dish cultures, 
can be cultivated in large number (about 10 000 worms/Petri-dish) and is cheap to maintain 
in the laboratory; it feeds primarily on bacteria such as Escherichia coli (E.coli).  
C. elegans is an animal, and so has, like other animals, muscles, a nervous system, 
a digestive system, and skin. It is a simple organism, both anatomically and genetically. 
The adult hermaphrodite contains exactly 959 cells and their position is constant. Sulston 
and co-workers (1983) mapped the origins and fates of all these cells during the 
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development (Sulston et al., 1983). The nervous system is the most complex organ in C. 
elegans – a third of the cells in the body are neurons (302 out of the 959 cells), located in 
the pharynx, ganglia in the head and tail and also in the ventral cord – and all the synapses, 
connections and neuronal circuits are well characterized, making possible to detect even 
minor defects (White et al., 1976; Albertson et al., 1976). The nervous system mediates a 
rich variety of behaviors, despite the small number of component neurons: animals move 
forward and backward by propagating sinusoidal waves along their bodies; they perform 
exploratory movements with their heads as they feed; and they respond to a number of 
sensory stimuli, including mechanical stimulation, changes in the chemical environement, 
osmolarity, and temperature (White et al., 1986). As mentioned before, C. elegans are 
transparent throughout the life-cycle allowing live imaging and thus, it is simple to track 
specific cells and follow cell lineages by light microscopy.  
 While the nervous system is of particular interest, this model organism has a short 
life cycle, which is dependent on temperature (see Figure 1.6). C. elegans goes through a 
reproductive life cycle (from egg to reproductive adult) in about 5.5 days at 15ºC, 3 days at 
20ºC and 2.5 days at 25ºC. The eggs are fertilized within the adult hermaphrodite and laid 
a few hours afterwards – at about the 40-cell stage. A single self-fertilized hermaphrodite 
is capable of producing 300 progeny. Each embryo will develop, hatch, and proceed 
through four larval stages (L1-L4) before becoming an adult (Nayak et al., 2005). Under 
food deprivation or stress, C. elegans can enter an alternative third larval stage called dauer 
state. Dauer larvae are stress-resistant and are long-lived; it can survive for months 
(Cassada & Russell, 1975). In a normal population, self-fertilizing hermaphrodites are 
more than 99%, leading to homozygosis of alleles and thus, making it possible to study 
large clonal populations. Males arise at a low frequency, due to meiotic chromosomal non-
disjunction. In the laboratory, crossing males can be used to produce progeny with desired 
genotypes which is of particular interest for genetic studies.  
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Figure 1.6- The simple life cycle and anatomy of C. elegans. (A) The larvae resemble the adults 
except in the lack of fully developed gonads, and their smaller size. The illustration shows the 
timing of developmental events at 25ºC, with hours since fertilization on the outside of the circle, 
and hours since hatching on the inside. Molts are indicated by solid black bars. (B) The adult 
hermaphrodite anatomy is simply observed under light microscopy. Above is an adult animal 
(length: 1mm). In the representation below the major organ systems are indicated. Adapted from 
www.plosbiology.org.  
 
 The importance of C. elegans for the study of human biology is twofold. One 
aspect is the startling finding that many of the genes in the C. elegans genome have close 
homologues in the human, and that many human disease genes are present in the worm 
(Gengyo-Ando et al., 1996; Wittenburg et al., 2000). The second is the ability to ask 
simple, direct questions of the C. elegans system and thus get simple, direct answers of 
universal significance. At least 42% of human disease-related genes have a C. elegans 
ortholog, suggesting that most biochemical pathways are conserved across evolution 
(Culetto & Sattelle, 2000). For these reasons, C. elegans has emerged as an attractive and 
powerful in vivo model system for studying pathological mechanisms in several major 
neurodegenerative disorders. The benefits of C. elegans as a model have led to the 
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development of multiple C. elegans systems designed for studying the effect of 
aggregation-prone proteins.  
 
Nevertheless, it should be pointed that there are limitations to studying 
neurodegeneration in C. elegans. Worms do not have myelination or an active immune 
system, so they are presumably not appropriate for the study of some neurodegenerative 
conditions such as multiple sclerosis. In practice, worm neurons are small and difficult to 
patch clamp, so electrophysiology studies are somehow although recordings can be made 
from single identified neurons (Ramot et al., 2008). 
 
1.8.1 C. elegans models of polyQ expansions  
 In agreement with the observations made in human disorders, polyQ proteins 
expressed in the C. elegans body wall muscle cells revealed a polyQ length-dependent 
aggregate formation and cellular toxicity (Satyal et al., 2000). Similar to human polyQ-
associated diseases, which shows a progressive aggravation of the disease symptoms with 
age, the phenotypes observed in the animals expressing expanded polyQ tracts (and not 
normal polyQ-lengths) increased as the animals aged (Morley et al., 2002). A relation 
between aggregation onset and age-associated cellular changes was shown for the first time 
in polyQ C. elegans models (Morley et al., 2002; Hsu et al., 2003; Morley & Morimoto, 
2004). In order to identify the protein factors that protect cells against the formation of 
protein aggregates, besides proteins involved in the aging pathway, Nollen and co-workers 
(2004) established transgenic C. elegans strains expressing Q35::YFP, the Q-length 
threshold associated with the age-dependent appearance of protein aggregation (Nollen et 
al., 2004). In order to investigate the effect of polyQ pathogenic motifs in neuronal cells 
and to determine if the expression of the same toxic species would affect differently 
distinct neuronal subtypes, Brignull and co-workers (2006) expressed polyQ expanded 
proteins throughout the C. elegans nervous system. By the expression of a range of polyQ 
lengths, they demonstrated, similarly to the polyQ C. elegans body wall muscle cells 
model, a polyQ length threshold of >Q40 for the formation of visible structures 
corresponding to immobile protein. Additionally, at the threshold Q-lengths, distinct 
neuronal subtypes were differently susceptible to the expanded polyQ protein (Brignull et 
al., 2006).  
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1.8.2 High-throughput screenings (HTS)  
 High-throughput screens (HTS) (genetic or pharmacological) using rodent models 
are very expensive and time-consuming and are limited to a small number of animals per 
treatment. A maintaining constant condition within each experiment, never mind between 
different research groups, is also very difficult with such complex organisms. Many 
research groups are recognizing the advantages of in vivo whole organism experiments 
using invertebrate animals. These advantages include rapid and inexpensive testing, as well 
as negligible animal welfare issues. Although in vitro cell-based HTS assays are 
commonly used, whole organism testing allows investigators to observe phenotypes that 
are well-characterized and biologically relevant.  
Invertebrate models such as C. elegans are therefore attractive as they offer much 
greater experimental flexibility and control in a better defined genetic and physiological 
background. As mentioned before, C. elegans has a well-characterized and visually 
accessible nervous system. The morphology, location and connectivity of each of its 302 
neurons are well defined. Combined with the wide array of genetic tools available to the C. 
elegans biologist and their capacity do grow in a 96-well plates in liquid culture, these 
properties make it amenable to HTS genetic and pharmacological (Lee et al., 2004). C. 
elegans neurodegeneration models have been used to test the effects of individual drugs 
(Parker et al., 2005; Locke et al., 2008) or relatively small collections of compounds (Wu 
et al., 2006; Voisine et al., 2007). Although large numbers of replicate C. elegans 
populations can be readily grown in small volumes, a previous hindrance in moving from 
low- to HTS was the requirement for manual manipulation and phenotypic scoring of 
worms. Advances have now overcome many of the practical limitations in using C. 
elegans models for HTS, most prominently the development of the Complex Object 
Parametric Analyzer and Sorter (a.k.a. the COPAS "worm sorter") (Pulak et al., 2006). The 
COPAS instrument was used in C. elegans by Burns and co-workers (2006) who 
demonstrated how this technology could be incorporated with a HTS digital imager and 
data management software for specifically scoring phenotypes (Burns et al., 2006). This 
instrument has been used for HTS of neurotoxins, suggesting that this instrument should be 
equally applicable for screening for neuroprotective compounds in many 
neurodegeneration models (Boyd et al., 2009).  
 
In the absence of generally accepted cell and animal models, and of any compounds 
that produce positive effects in the clinical setting, a strategy could be to assess two 
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characteristics of MJD and focus on those drugs that work in several assays. Based on all 
this, this thesis will focus on the idea that the transgenic C. elegans model of MJD 
pathogenesis mentioned above (Teixeira-Castro et al, 2011a) - in which pan-neuronal 
expression of AT3q130 proteins cause neuron-specific aggregation and this aggregation 
phenotype correlates with locomotion impairment in the animal and both aggregation and 
behavior phenotypes aggravates with age, which mimic the human disease - can be used 
for the identification of compounds that recover mutant ATXN3 aggregation and its 
associated neurological dysfunction. We used the AT3q130 model for a therapeutic 
approach (i) focusing on mitochondria and (ii) for the screening of 1120 off-patent FDA-
approved compounds from the Prestwick Chemical LibraryTM (Prestwick Chemical, 
France). Aggregation load and locomotion defects were used as readouts for the 
assessment of drug treatment efficacy.  
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1.9 Objectives 
 
 Little was known about therapeutic compounds that effectively prevent 
neurodegeneration in MJD patients when this experimental work was started. Bearing in 
mind the impact of neurodegenerative diseases in the society and that the mechanisms by 
which the expansion of the CAG-repeat of ATXN3 cause neurological dysfunction and 
disease are still unclear, our goals were: 
 
 
Pharmacologic modulation of cellular pathways involved in polyQ pathogenesis - 
targeting mitochondria: 
1. To define the toxicity threshold of Cr in C. elegans WT (N2); 
2. To define the toxicity threshold of Cr in the transgenic C. elegans model of MJD 
pathogenesis (AT3q130); 
3. To establish whether Cr treatment ameliorates the phenotype of aggregation of 
mutant ATXN3 in the transgenic C. elegans model of MJD pathogenesis 
(AT3q130); 
4. To evaluate if Cr ameliorates the behavior and motor function in the transgenic C. 
elegans model of MJD pathogenesis (AT3q130).  
 
 
Screening of a library of FDA-approved out-of-patent drug molecules – 
hypothesis-free approach: 
1. To select non-toxic compounds from 1120 small molecules from the Prestwick 
Chemical LibraryTM (Prestwick Chemical, France) using a High-throughput 
pharmacological screening; 
2. To identify drug compounds those improve the motor neuron-regulated locomotion 
defect in the transgenic C. elegans model of MJD pathogenesis (AT3q130).  
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2.1. C. elegans strains culture and general methods 
 
 Nematodes were grown on NGM – nematode growth medium -  plates seeded with 
E. coli OP50 strain at 20ºC, according to standard methods (unless otherwise noted) 
(Brenner, 1974). Populations were synchronized either by collecting embryos laid by adult 
animals within a 3-h period. All animals were scored at the same chronological age. 
Experiments were repeated three to four times.  
 
 
2.2. Creatine treatment 
 
Cr treatment was performed in regular NGM plates (Brenner, 1974). E. coli OP50 
cultures were supplemented with Cr powder obtained from Sigma (C0780, St. Louis, MO, 
USA), at the indicated percentages. Plates were seeded with 100µL of OP50/Cr and left at 
room temperature to dry. We have also added Cr powder on standard solid media (before 
submitting the media to high temperature and pressure – 121ºC 20min). AT3q130 animals 
were always grown on Cr plates at least one generation prior to the beginning of the 
assays. For the toxicity screen, animals were observed every day and growth rates, fertility 
and survival parameters were evaluated. After determination of the safe toxicity range for 
Cr, synchronized day 4 animals (post-hatching) were scored for motility defects and 
alteration in the aggregation profile, using confocal imaging.  
 
 
2.3. C. elegans treatment with compounds from the Prestwick Chemical 
LibraryTM 
 
HTS were performed in 96-well plates in liquid culture (Voisine et al., 2007), with 
the following modifications: each well contained a final volume of 60 µL, including 20–25 
animals in egg stage, drug at the appropriate concentration and OP50 bacteria to a final OD 
of 0.8 measured in the microplate reader (Bio-Rad microplate reader 680). Animals and 
bacteria were resuspended in S-medium supplemented with streptomycin, penicillin and 
nystatin (Sigma). Worms were grown with continuous shaking at 180 rpm at 20°C. The 
effect of compounds on C. elegans physiology is monitored by the rate at which the OP50 
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food suspension was consumed, as a read out for C. elegans growth, survival or fecundity. 
The absorbance (OD 595nm) was measured daily in the microplate reader. We used WT 
animals when determining compound concentration and AT3q130 animals for all the other 
assays. At day 4, AT3q130-drug-treated and control animals (N2) were imaged using a 
confocal microscope (Olympus FV1000 - Japan) and tested for motility defects.  
 
 
2.4. Motility assays 
 
 All assays were performed at room temperature (~20ºC) using synchronized 
animals grown at 20ºC. Five 4-days old animals were placed simultaneously in the middle 
of a freshly seeded plate, equilibrated at 20ºC. Animals remaining inside a 1cm circle after 
1min were scored as locomotion defective (Gidalevitz et al., 2006). Experiments were 
repeated until an n-value of at least 150 animals.  
 
 
2.5. Confocal imaging 
 
 All images were obtained on an Olympus FV1000 (Japan) confocal microscope, 
under 60x oil objective. Animals four-days-old were immobilized with 1.5 mM levamisole 
and mounted on a 3% agarose pad. Z-series imaging was taken of all the C. elegans lines 
generated, using 514nm laser excitation for YFP fusion proteins. The pinhole was adjusted 
to 1.0 Airy unit of optical slice and a scan was taken every ~0.5 µm along the Z-axis.  
 
 
2.6. Quantification of the aggregates 
 
C. elegans fluorescent images were acquired using the Olympus FV1000 (Japan) 
confocal microscope. Confocal microscope parameters were set using Hi-Lo pallet, such 
that protein foci and not diffuse fluorescent areas of the animals nervous system presented 
pixel intensity higher than 255. The z-stack was collapsed and the aggregate load of each 
animal (per area unit) was calculated on an imaging processing application using 
MeVisLab as a platform (Teixeira-Castro et al., 2011b).  
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3.1. Screening of therapeutic compounds in a C. elegans model of MJD: 
targeting mitochondria  
 
 There is considerable evidence for bioenergetic defects in MJD (Yu et al., 2009). 
We have tested the effect of a candidate compound targeting mitochondrial toxicity in our 
C. elegans model of MJD: Cr. We chose to test this compound mainly because Cr was 
shown to be neuroprotective in several in vitro and in vivo models of AD, HD, PD and of 
ALS (reviewed in Beal, 2011) and to target mitochondria and stabilize it.  
We examined whether Cr, which may exert neuroprotective effects by increasing 
PCr levels or by stabilizing the mitochondrial toxicity, had beneficial effects in mutant 
ATXN3-mediated motor dysfunction and aggregation.  
 
 
3.1.1. Determination of Cr safe concentration range in C. elegans 
 
 Cr showed very low solubility in any of the solvents tested (H2O and HCl 0.02M, 
0.05M - data not shown), so instead of growing the animals in liquid medium, we 
supplemented the food source (OP50 culture) with Cr powder and grew the WT animals on 
standard solid media. We have also added Cr powder to standard solid media (before 
submitting the media to high temperature and pressure – 121ºC 20min) and grew the WT 
animals. The final Cr concentrations tested were 1, 2 and 3%. We assessed survival, 
fecundity and animal growth to determine the highest non-toxic concentration of Cr that 
can be tolerated by C. elegans, when grown in standard conditions (see Figure 3.1). We 
found that the highest safe concentration was <2% for Cr-supplemented media. Animals 
grown in 3% Cr (food and medium-supplemented) showed a slight developmental delay 
and reduced brood size (Figure 3.1).  
To further dissect the effects of Cr, we decided to grow mutant-ATXN3 animals 
also at intermediate concentrations (see Figure 3.2), using the same conditions. Also for 
AT3q130 animals <2% Cr was set as the highest safe concentration tolerated by the 
nematodes (Figure 3.2). Along with that, we decided to interrupt the addition of Cr powder 
to standard solid media because we found it hard to predict if Cr was resistant to the 
processing in the autoclave.  
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Figure 3.1- WT animals (N2) were grown in NGM media containing Cr or with NGM plates seeded with OP50 supplemented with Cr 
at the indicated concentrations. When treated with 3% Cr in both conditions, animals showed developmental delay (reduced length and 
thickness) and reduced progeny size (each photo is representative of the entire plate). The highest safe concentration was set as <2% for 
Creatine-supplemented media. Pictures show day 4 (post-hatching) age-synchronized animals. Scale bar, 200µm.  
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Figure 3.2- AT3q130 animals were grown in NGM media containing Cr or seeded with OP50 supplemented with Cr at the indicated 
concentrations. When treated with 2% Cr animals showed no considerable developmental delay (each photo is representative of the entire 
plate) The highest safe concentration was set as <2% for Cr-supplemented media. Pictures show day 4 (post-hatching) age-matched animals. 
Scale bar, 200µm.  
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3.1.2. Determining the effect of Cr in mutant ATXN3-mediated motor dysfunction in 
C. elegans 
 
 We evaluated Cr efficacy to rescue neuronal dysfunction in our C. elegans model of 
MJD pathogenesis. Expression of mutant ATXN3 (AT3q130) in all C. elegans neuronal 
cells resulted in neuronal cell-type-specific aggregation that correlated with toxicity 
(Teixeira-Castro et al., 2011a). AT3q130 animals were grown on standard solid media 
supplemented with or without Cr powder for 4 days, and then tested for defects in 
locomotion, by employing a motility assay (Gidalevitz et al., 2006).  
In our C. elegans model of MJD pathogenesis, Cr food supplementation had limited 
effect in mutant ATXN3-mediated neuronal dysfunction at all concentrations tested (see 
Figure 3.3), not even after three generations (data not shown).  
 
 
Figure 3.3- AT3q130 animals treatment with Cr targeting mitochondrial toxicity. Day 
4 AT3q130 animals treated with Cr were subjected to the motility assay. Cr treatment 
showed no significant rescue of motor dysfunction. Motility data are the mean ± SD, at 
least 150 animals per data point.  
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3.1.3. Effect of Cr in mutant ATXN3-mediated aggregation 
 
To determine if Cr produced potential alterations in mutant-ATXN3 aggregation 
profile in the animals, despite the absence of effect on motor dysfunction, we performed 
live confocal imaging assays in day 4 Cr-treated and vehicle-treated animals (Figure 3.4A).  
Quantification of the number of aggregates showed that AT3q130 animals fed with 
bacteria supplemented with Cr did not show any significant differences in aggregation (see 
Figure 3.4B). However, Cr at 1.5 % seemed to have a tendency to a reduction in the 
aggregation load, which did not reach statistical significance.  
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Figure 3.4-Creatine treatment of mutant ATXN3 animals showed no significant 
rescue of the number of aggregates per area unit. (B) Creatine at 1.5 % resulted in a 
tendency to a reduction in aggregation that did not reach statistical significance. 
Quantification of the number of aggregates per area was performed using a novel imaging 
processing application for aggregate quantification in C. elegans (Teixeira-Castro et al., 
2011b), and values are the mean ± SD of 3 or more animals per group. (A) The images 
were obtained using on an Olympus FV1000 (Japan) confocal microscope. Scale bar, 50 
µm.  
 
 
 
3.2. Screening of therapeutic compounds in a C. elegans model of MJD: 
hypothesis-free approach 
 
 
3.2.1. Determination of compound concentration range for drug screening in C. 
elegans 
 
 We have continued our search for small molecules that modulate mutant ATXN3 
pathogenesis by using a hypothesis-free approach. In order to achieve that we have started 
testing a library of 1120 FDA-approved out-of-patent drug molecules. Figure 3.5 shows the 
flow chart of the screening. The first point of the screening was to identify and exclude 
small molecules that were toxic to the animals. One of the major disadvantages of using C. 
elegans in HTS could arise from the possible toxicity of the compounds in this animal. In 
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order to exclude the effects of high toxicity in our study, we used a systematic method, 
previously described by Voisine and co-workers (Voisine et al., 2007), for selecting 
optimal drug concentrations in C. elegans - the food clearance assay. This is a simple assay 
that uses a small amount of compound and is amenable to high-throughput format (96-well 
plates). Taking advantage of the short life cycle and the capacity of C. elegans to grow in 
liquid culture of E. coli, compounds were monitored by measuring the rate at which the 
food source (OP50 bacteria suspension) was consumed. Optical density was measured 
every day (from day 1 to day 8) at 595 nm (OD595) (see Figure 3.5). Each adult is capable 
of producing hundreds of progeny that rapidly eat the limited bacteria source in non-treated 
or vehicle-treated animals. At 20°C, after 4 days the optical density (OD) decreased 
significantly. A drug dosage was considered non-toxic to WT animals, if it did not affect 
growth, survival and fecundity. We have to take into account the fact that these drugs are 
solubilized in dimethyl sulfoxide (DMSO) and are very distinct chemically. Because of 
that, we decided to test two concentrations in which the highest corresponds to the highest 
DMSO concentration tolerated by the animals (1%) and the lowest concentration 
corresponds to half (0,5%). So, we tested 25µM and 50µM for each drug. Figure 3.6 
shows, as examples, the toxicity data for 5 of the compounds tested, named after the library 
designation – Prestwick-211 to Prestwick-215. The graphs show that at both concentrations 
tested Prestw-212 was toxic to the animals, since the OD values did not significantly 
decrease over time. Visual inspection of the plates confirmed the OD results, since we 
observed that the drug caused strong developmental delay. In contrast, animals treated with 
Prestw-211, -213, -214 and -215 looked normal under the dissecting scope (data not 
shown).  
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Figure 3.5- Experimental design for screening potential therapeutic compounds for 
MJD pathogenesis in C. elegans. The first step is to determine the range of safe 
concentrations for each compound, using the food clearance assay. The rate at which the 
food source is consumed by WT animals is a good indication of normal growth, survival 
and fecundity. Next, mutant ATXN3 animals are grown with different concentrations of 
each small molecule and assayed for locomotion defects and aggregation profile. 
Compounds that cause rescue of locomotion impairment and also a reduction of the 
aggregation load in AT3q130 animals are considered good candidates for testing in higher 
model organisms.  
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Figure 3.6- Toxicity evaluation of Prestwick library compounds using the food 
clearance assay. Example of 5 of the compounds tested is given here. At both 
concentrations tested Prestw-212 was toxic to the animals. The OD of E. coli is reported 
daily for each drug at 25 and 50 µM. The mean OD is calculated for each day from 
triplicate samples and plotted over time.  
 
 
 The main goal of the first step was to select non-toxic compounds from the small 
molecule library that will be subsequently used throughout the project. At this point we 
should be able to exclude the majority of the highly toxic compounds from the library. We 
will continue our study only with the compounds that fulfill this non-toxicity criterion. So 
far we already have tested 900 compounds, 264 of which were toxic at the concentrations 
tested and were excluded from further testing. A subset of the compounds was toxic when 
tested at 50µM and not at 25µM. Based on this, we selected 617 compounds safe at 50µM 
and 19 safe at 25µM that satisfied our non-toxicity criteria and continued for the next step: 
to determine the effect of the small molecules in the locomotion impairment of AT3q130 
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animals. Table 3.1 shows the toxicity data for compounds already tested. Drug toxicity was 
classified using the following criteria: Safe drug – all replicates at all days and both 
concentrations showed no toxicity; Toxic drug - all replicates at all days and both 
concentrations showed toxicity; Likely safe – at both concentrations and all days, at least 2 
replicates showed no toxicity; Likely toxic - at both concentrations and all days, at least 2 
replicates showed toxicity; Safe at 25µM - at 25µM only and on all days, all 3 replicates 
showed no toxicity; Likely Safe at 25µM – at 25µM only and on all days, at least 2 
replicates showed no toxicity; Developmental delay – at both concentrations and at days 
4/5 the drug is considered toxic, but all replicates showed no toxicity at day 6 at both 
concentrations; Developmental delay at 25µM – at both concentrations and at days 4/5 the 
drug is considered toxic, but all replicates showed no toxicity at day 6 at 25µM only; 
Unclear toxicity – all other situations – includes cases for instance where toxicity is higher 
at 50uM than 25uM. We are currently assessing the toxicity of the remaining 220 
compounds.  
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Table 3.1- Toxicity data for the compounds tested.  
Prestw 
Number 
Therapeutic 
Group Mechanism Side Effect(s) Veredict 
Prestw-29 
Analgesic; 
Antipyretic; 
Antiinflammatory 
- 
Nausea; 
Seizure; 
Drowsiness; 
Hemolytic 
anemia 
Likely Safe 
Prestw-30 Antipyrine metabolite - Irritant Safe at 25 µM 
Prestw-38 Antihypertensor Ganglion blocking agent - Safe at 25 µM 
Prestw-101 Emetic; Antiparkinson 
D1 agonist; 
D2 agonist 
Migraine; 
Asthenia; 
Tachycardia; 
Hypotensive; 
Cardivascular 
collapse 
Safe at 25 µM 
Prestw-104 Antiulcerative H2 histaminic antagonist - Likely Safe 
Prestw-123 Choleretic - - Likely Safe 
Prestw-124 - P450 inhibitor - Likely Safe at 25 µM 
Prestw-125 Antipsychotic; Tranquilizer Dopamine antagonist - Likely Safe 
Prestw-127 Antibacterial; Antifungal 
Sterol 14-demethylase 
inhibitor - Likely Safe 
Prestw-129 Antiulcerative M1 antagonist; Anticholinergic - Likely Safe 
Prestw-223 Nasal decongestant; Vasoconstrictor Adrenergic alpha-agonists - Likely Safe 
Prestw-224 Vasoconstrictor; Decongestant 
Partial alpha2A agonist; 
5-HT1A agonist; 
5-HT1B agonist; 
5-HT1D agonist; 
5-HT1C mixed antagonist 
agonist 
- Likely Safe 
Prestw-225 Analgesic; Antipyretic Cyclooxygenase inhibitor - Likely Safe 
Prestw-226 
Antifungal; 
Antibacterial; 
Antiinflammatory 
Enzymatic inductor 
Headhache; 
Antabuse effect; 
Teratogenic 
(animal) 
Likely Safe at 
25 µM 
Prestw-227 
Antihistaminic; 
Local anesthesic; 
Antibacterial; 
Antifungal 
H1 antagonist Allergic Likely Safe at 25 µM 
Prestw-257 Keratolytic - - Likely Safe 
Prestw-258 Antihistaminic Sedative H1 antagonist 
Nausea, vomiting 
Thrombolytic 
anemia 
Sedation 
Likely Safe 
Prestw-259 Diuretic Na
+ Cl- uptake 
inhibitor - Safe at 25 µM 
Prestw-260 Anthelmintic Modulates cell membrane permeability Bradycardia Safe at 25 µM 
Prestw-261 Progestogen - - Likely Safe at 25 µM 
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3.2.2. Screening for compounds that rescued mutant ATXN3-mediated motor 
dysfunction 
 
 Secondly, we aimed to investigate the impact of the hit compounds on neuronal 
dysfunction caused by mutant ATXN3 expression (Figure 3.7). For this we perform 
motility assays in animals treated with the small molecules that passed the non-toxicity 
condition, looking for compounds that significantly improve the 40% locomotion defective 
phenotype observed in AT3q130 expressing animals. We have tested 20 compounds, two 
of which (Prestw-38 and Prestw-227) revealed to be modulators of mutant ATXN3-
mediated motor impairment.  
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Figure 3.7- Treatment of AT3q130-expressing animals with the small molecule 
Prestwick-38 and Prestwick-227 showed an improvement of motor function (A and 
C). Day 4 mutant ATXN3 expressing animals treated with the small molecules Prestw-29, 
-30, -101, -104, -123, -124, -125, -127, -129 -223, -224, -225, -226, -257, -258, -259, -260, 
-261 showed no significant improvement in motility. Prestw-38and Prestw-227 were able 
to rescue the motor dysfunction of AT3q130 animals. Motility data are the mean ± SD, 
with at least 150 animals per data point. Student´s test, *, p<0.05  
 
 
3.2.3. Assessment of the effect of phenotype-improving mutant ATXN3 aggregation 
 
To determine if the effects of Prestw-38 and Prestw-227 on motor dysfunction were 
coupled with potential alterations in mutant ATXN3 aggregation profile in the animals, we 
performed live confocal imaging assays in day 4 treated and non-treated animals. 
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Aggregate quantification of animals treated with the small molecule Prestw38 revealed no 
major differences in the aggregation load (see Figure 3.8). However, Prestw-227 treated 
animals showed a significant reduction in the number of aggregates per area and in the area 
of aggregates per area (see Figure 3.8). The number of aggregates also decreased, however 
without reaching statistical significance. Ongoing experiments aim to determine the effect 
of these two different compounds in total mutant ATXN3-protein levels.  
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Figure 3.8- Animals treated with Prestw-38 revealed no major differences in the 
aggregation load and Prestw-227 rescue ataxin-3-mediated aggregation. AT3q130 
animals treated with 25µM of Prestw-38 showed a mild reduction in the aggregation 
phenotype and Prestw227 treated animals showed a significant reduction in the number of 
aggregates per area and in the area of aggregates per area at day4 of adulthood. Scale bar, 
50 µm (A). The images were obtained using an Olympus FV1000 confocal microscope. 
Quantifications of aggregates (B, C, D) were performed using our novel imaging 
processing application for aggregates quantification in C. elegans (Teixeira-Castro et al., 
2011b), and values are the mean ± SD of seven or more animals per group. Student´s test, 
*, p<0.05.  
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Chapter IV 
Discussion 
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 In the last years, several human diseases, including neurodegenerative diseases like 
AD, PD, ALS and several polyQ disorders, have been shown to arise from the misfolding 
and aggregation of an underlying protein (Gatchel & Zoghbi, 2005). Inappropriate 
aggregation of proteins is normally prevented by complex cellular quality control 
mechanisms. Nevertheless, under certain circumstances, an unusual subset of proteins is 
able to aggregate within or around cells. A more thorough understanding of the factors that 
influence this balance is the key for determining how protein aggregation diseases arise 
and may provide novel opportunities for developing effective therapies against them.  
 With this work, we took advantage of our C. elegans model and approach for 
therapeutic value in MJD, using a candidate-drug strategy. Given the lack of positive 
effects, we initiated a screening to find new bioactive compounds using a hypothesis-free 
approach. These compounds may provide candidate drugs to test in higher organism 
models of the disease, but they may also provide clues concerning pathogenic mechanisms 
of MJD.  
 
 
4.1 Targeting mitochondria as a therapeutic approach for MJD  
 
As we already know, mitochondrial dysfunction has been implicated in ageing, 
which is a major risk factor for progressive neurodegenerative diseases. There is growing 
evidence that mitochondrial dysfunction may play an important role in neurodegeneration 
(for review see Knott et al., 2008). Therefore, targeting mitochondrial toxicity may be a 
valuable strategy for the treatment of many neurodegenerative disorders, like MJD. It is 
known that the brain also has cellular defense systems against oxidative stress. These 
systems include high levels of several antioxidant enzymes (e.g., catalase, SOD, GSH-px, 
and GSSG-R) (Lee et al., 2000). Because of the late onset of the MJD, Yu and co-workers 
(2009) hypothesized that the accumulated oxidative stress or/and defective antioxidant 
enzyme ability might be contributory factors in the pathogenesis of MJD. Their results 
demonstrated that mtDNA copy numbers are reduced in mutant ATXN3 expressing cells 
and MJD patient’s leukocyte samples. Moreover, the amount of the common mtDNA 
4,977-bp deletion is superior in MJD patients compared with that in normal individuals. 
So, mutant ATXN3 may influence the activity of enzymatic components to remove O2- and 
H2O2 successfully and promote mtDNA damage or depletion, which leads to mitochondria 
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dysfunction (Yu et al., 2009). There is therefore evidence of mitochondrial dysfunction in 
MJD. Although we did not address the presence of mitochondrial dysfunction in our C. 
elegans model of MJD, there is evidence of mtDNA dysfunction in a transgenic mouse 
model of MJD generated in our lab (results from a pilot-study – Nadya Kazachkova, 
personal communication, March 2011). These preliminary results support the hypothesis of 
an association between mtDNA dysfunction (depletion and deletion) with aging and 
neurodegeneration.  
 
Since Cr had produced significant neuroprotection in the HD toxic rat model 
(Matthews et al., 1998), numerous studies have indicated that supplementation of Cr could 
promote strong neuroprotective effects. Cr administration also protects against glutamate 
and β-amyloid toxicity in rat hippocampal neurons (Brewer &Wallimann, 2000). Similar 
results were obtained in the R6/2 and the N-171-82Q transgenic mouse models of HD, 
even when Cr significantly improves survival, improves motor performance, slows the 
development of brain atrophy, increases brain ATP levels, and delays atrophy of striatal 
neurons and the formation of Htt-positive aggregates (Ferrante et al., 2000; Andreassen et 
al., 2001; Dedeoglu et al., 2003). Additionally, oral administration of Cr produces a dose-
dependent improvement in motor performance and extends survival in G93A transgenic 
ALS mice, where it protects against loss of both motor neurons and substantia nigra 
neurons (Klivenyi et al., 1999) but Cr does not exert a beneficial effect on skeletal muscle 
function in the same transgenic mice (Derave et al., 2003).Based on these evidences, we 
decided to make use of our C. elegans model of. MJD to validate the approach of 
correcting mitochondrial dysfunction with Cr food supplementation as a therapeutic 
strategy for MJD.Unfortunately, Cr food supplementation had limited effect in MJD 
pathogenesis in mutant ATXN3-mediated neuronal dysfunction.This was an unexpected 
result given all the successful results in the previous research. On the other hand, it is 
important to notice that we are not sure if Cr was consumed or absorbed by the nematodes. 
This work opened several questions that we aim to answer in the near future. Assaying 
ATP and ADP levels provides a measure of the instantly available energy (Braeckman et 
al., 2002).We now propose to study mitochondrial dysfunction in our C. elegans model of 
MJD, measuring the number of mtDNA copies, the frequency of mtDNA deletions and the 
levels of ATP, because if Cr functions ATP levels in cells should increase (Tsang & 
Lemire, 2003). 
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 The neuroprotective effects of Cr in HD and PD in transgenic mice were described 
to be potentiated when in combination with CoQ10 (Yang et al., 2009). The combination of 
the two compounds produced additive neuroprotective effects against dopamine depletion 
in the striatum and loss of tyrosine hydroxylase neurons in the substantia nigra pars 
compacta (SNpc). The combination treatment resulted in significant reduction in lipid 
peroxidation and pathologic α-synuclein accumulation in the SNpc neurons. In the R6/2 
transgenic mouse model of HD, the combination of CoQ and Cr produced additive effects 
in terms of improving motor performance and extending survival. These results suggest 
that combination therapy using CoQ10 and Cr may be useful in the treatment of 
neurodegenerative diseases such as MJD. In addition, it was found that the combination of 
Cr and minocycline (a tetracycline antibiotic with neuroprotective properties) also 
provided additive neuroprotective effects in the G93A mouse model of ALS (Zhang et al., 
2003). In the same way, additive neuroprotective effects of Cr and a COX-2 inhibitor were 
found in the MPTP mouse model of PD and the G93A transgenic mouse model of ALS 
(Klivenyi et al., 2003; Klivenyi et al., 2004). These findings also suggest that combinations 
of therapies targeting different disease mechanisms may be a useful strategy in the 
treatment of neurodegenerative diseases and may be a future approach for our C elegans 
model of MJD.  
 
 
4.2 HTS for the identification of MJD therapeutic compounds 
 
 The development of C. elegans models for the study the pathogenesis of 
neurodegenerative diseases has contributed to the understanding of the disorders. They 
provide a major advance for testing or evaluating therapeutics. If therapeutics effects in C. 
elegans are shown to be predictive of beneficial effects in transgenic mouse models 
(mammalian systems), then this model will allow rapid screening of new therapies. One 
clear advantage of C elegans over other multicellular model organisms for 
neurodegeneration is its capacity to grow in liquid medium, in standard 96-well microtiter 
plates. Growth in a 96-well format permits application of HTS technologies developed for 
drug discovery.  
 In the present study, we have developed strategies for efficiently assessing 
therapeutic efficacy of compounds in our C. elegans model of MJD. We used the AT3q130 
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model for the screening of 1120 off-patent FDA-approved compounds from the Prestwick 
Chemical LibraryTM (Prestwick Chemical, France) and searched for small molecules that 
modulate mutant ATXN3 pathogenesis. The majority of the small molecules, 90%, are 
marketed drugs and the remaining 10% are bioactive alkaloids or related substances.The 
active compounds were selected for their high chemical and pharmacological diversity as 
well as for their known bioavailability and safety in humans.  
 The main goal of the first step was to select non-toxic compounds from the small 
molecule library that will be subsequently used throughout the project. We excluded the 
majority of the highly toxic compounds from the library and continued our study only with 
the compounds that fulfilled this non-toxicity criterion.  
 The main objective of the current project is of course to identify drug compounds 
that improve motor neuron-regulated coordination in our MJD pathogenesis model. In 
parallel with the toxicity analyses, we started performing motility assays of AT3q130 
animals treated with the small molecules that passed the non-toxicity condition. Our study 
of the first set of compounds (Prestw-29, Prestw-30, Prestw-38, Prestw-101, Prestw-104, 
Prestw-123, Prestw-124, Prestw-125, Prestw-127, Prestw-129, Prestw-223, Prestw-224, 
Prestw-225, Prestw-226, Prestw-227, Prestw-257, Prestw-258, Prestw-259, Prestw-260 and 
Prestw-261) showed a significant reduction in the percentage of mutant ATXN3 animals 
that present locomotion defects, when treated with Prestw-38 and Prestw-227. Regarding 
Prestw-38, we simply know that it corresponds to the compound Hexamethonium 
Dibromide Dihydrate (C12H34Br2N2O2) and that it belongs to the therapeutic group of 
antihypertensors. Prestw-227 corresponds to the compound Clemizole Hydrochloride 
(C19H21Cl2N3) and it belongs to the therapeutic group of antihistaminic, local anesthetics, 
antibacterial and antifungal drugs, acting as an H1 antagonist.  
One of the main biological markers of all polyQ disorders is the formation of 
protein aggregates that correlate with pathogenesis. Bearing this in mind, we determined 
whether these two compounds (Prestw-38 and Prestw-227) modulated mutant ATXN3 
aggregation in vivo. Prestw-227 treated animals (and not Prestw-38) showed a significant 
reduction in the aggregation phenotype, suggesting that these two compounds may impact 
positively in mutant ATXN3-mediated pathogenesis through distinct cellular 
mechanisms/pathways.  
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 In recent years, it has become progressively clear that many neurodegenerative 
conditions involve aggregation and deposition of misfolded proteins. PolyQ diseases, like 
MJD, comprise one of the most common groups of inherited neurodegenerative disorders. 
The etiopathology of these disorders is extremely complex and heterogeneous. The most 
outstanding evidence pointing to the complexity of these diseases is that to date no single 
drug has been developed that can prevent the degenerative process or restore viability of 
neurons that are dying.  
 Neuroprotective compounds targeting identified pathological mechanisms of 
diseases have the potential to delay the onset and to slow the progression of these diseases. 
Various experimental studies in models systems have validated energy insufficiency as a 
promising therapeutic approach. Compounds such as Cr and CoQ10 buffer neuronal 
energy demands and are attractive candidates for targeting this important disease 
mechanism. Considering the widespread effects of Cr supplementation, one may conclude 
that this compound could be one of the most promising supplements in the therapeutic 
field. However, we should be alert that several therapeutic effects attributed to this 
supplement are still speculative. In other terms, although in vitro and animal studies have 
provided strong reason for clinical Cr benefits, the number of randomized controlled trials 
is very limited.  
 
Concerning our results, the main conclusions are: 
 Cr treatment showed limited effects in MJD pathogenesis in our C. elegans 
model; 
 264 out of 1120 compounds from the Prestwick Chemical LibraryTM were 
toxic and were excluded from further testing; 
 We selected 617 compounds safe at 50µM and 19 safe at 25µM that satisfy 
our non-toxicity criteria; 
 We started a motility analysis with the safe compounds, having completed 
the analysis for 20 compounds; 
 We have identified two compounds that reduced mutant ATXN3-mediated 
neuronal dysfunction; 
 We have identified one small molecule that significantly reduced the 
aggregation load caused by pan-neuronal expression of mutant ATXN3; 
 We have validated our C. elegans model of MJD for the screening of novel 
therapies for MJD.  
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This work opened several questions that we aim to answer in the near future. We 
will study mitochondrial dysfunction in our C. elegans model of MJD, measuring the 
mtDNA copy numbers, the frequency of mtDNA deletions and the levels of ATP. We 
believe that the measurement of ATP will provide a measure of energy available 
immediately after Cr supplementation and we will able to know the extent to which Cr is 
metabolized by our model. We will also analyze enzyme activities of MRC complexes. 
The MRC is composed of five electron transporting protein complexes (complex I to 
complex V) and the structure, metabolism, and bioenergetics of the nematode MRC are 
very similar to the mammalian counterpart, so many pathways of intermediary metabolism 
are conserved in C. elegans (Murfitt, et al., 1976; O’Riordan, et al., 1989; Wadsworth & 
Riddle, 1989).  
 With regard to combination therapies, many results suggest that combinations of 
therapies targeting distinct pathogenic mechanisms may be a useful strategy in the 
treatment of MJD. Considering this, whether Cr is actually at acceptable levels in our 
model or not, we can try a combination of drugs to a possible potentiation of effects.  
 
Observing the identification of potential therapeutic compounds for testing in our C 
elegans model of MJD, our results are promising because two non-toxic compounds 
revealed to be modulators of mutant ataxin-3-mediated motor dysfunction which means 
that we are in the presence of compounds able to modulate the pathways involved in 
mutant ATXN3 pathogenesis. Regarding the effects of these compounds on ATXN3 
aggregation, we will use FRAP to assess protein solubility states. This can be 
accomplished by photobleaching a region of a neuronal cell (region of interest) with a 
high-intensity laser pulse, and the movement of unbleached molecules from neighboring 
areas into the bleached area is recorded by time-lapse microscopy. We are also currently 
performing pharmacogenetic studies to determine drug target(s). This approach will allow 
us to complete the characterization of the hit compounds and establish aggregation-
behavior correlates. Additionally we will study the impact of these drugs on mutant 
ATXN3-protein levels, we will exclude the drugs that may be acting at the level of the 
promoter by quantitative Real Time PCR (qRT-PCR) and perform Western-blot analysis to 
determine if the others small molecules modulates aggregation or/and neurological 
dysfunction by altering the steady-state levels of the mutant ATXN3-protein. Next, we will 
biochemically quantify the aggregate load of our C. elegans model, to establish a 
quantitative correlation between the presence of aggregates and ATXN3-induced 
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pathogenesis, and for that we will use a technique named Seprion (Sathasivam et al., 
2009). We also will determine which intermediate species of aggregation are more toxic by 
comparing the profile of the aggregation-prone species, when run in agarose gels, with the 
impact on the animals’ behavior, and for that we will perform NAGE (native agarose-gel 
electrophoresis) (vanHam et al., 2010) that will give us insights regarding native ATXN3 
oligomeric species and SDD-AGE (Semi-Denaturating Detergent Agarose Gel 
Electrophoresis) (Halfmann and Lindquist, 2008) that is performed in denaturant 
conditions. 
We expect to complete this study soon and should be able to identify several 
efficacious compounds that we will start to test in our MJD (CMVMJD135) mouse model 
(Silva-Fernandes et al., 2010) in the near future.  
This HTS will also give us insight into the mechanisms of MJD pathogenesis. 
Additionally, the hit compound(s) identified in this screening may represent chemical 
“scaffolds” to be optimized by chemical modification and constitute strong lead 
compounds for the development of therapeutics for human polyQ diseases. 
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